Skip to main content
Psychedex
Sources
47
18 strong · 21 moderate · 8 weak

Studies and references cited across this article, graded by evidence strength.

Claims checked
119
73verified7partial39inconclusive

Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.

Generated
Apr 28, 2026 · pipeline-v5
Values approved
116/118 (98%)

Data points an editor reviewed and accepted for publication.

01

Value Provenance

Dosing

oraltrace

FieldPublishedAI ProposedConfidence
Threshold5 mg5 mghigh
Low5–10 mg5–10 mghigh
Common10–20 mg10–20 mghigh
Strong20–40 mg20–40 mghigh
Heavy40+ mg40+ mghigh
Editorial

Therapeutic range (5–10 mg IR) from FDA labeling, AASM guidelines (Ref 15), European guidelines (Ref 34), and Salvà 1995 (Ref 27). Supratherapeutic ranges from Schoedel 2016 (Ref 22: 15 mg and 30 mg in abuse potential RCT) and Wang 2011 (Ref 30: 200–500 mg/day extreme cases). Threshold at 5 mg (minimum approved dose for women/elderly). Light range spans approved therapeutic doses. Common range begins at upper therapeutic limit and extends through 2× max dose. Strong range covers documented abuse-potential study doses. Heavy at 40+ mg based on case report data. Bioavailability ~70% from Ref 27.

Reasoning

Therapeutic range (5–10 mg IR) from FDA labeling, AASM guidelines (Ref 15), European guidelines (Ref 34), and Salvà 1995 (Ref 27). Supratherapeutic ranges from Schoedel 2016 (Ref 22: 15 mg and 30 mg in abuse potential RCT) and Wang 2011 (Ref 30: 200–500 mg/day extreme cases). Threshold at 5 mg (minimum approved dose for women/elderly). Light range spans approved therapeutic doses. Common range begins at upper therapeutic limit and extends through 2× max dose. Strong range covers documented abuse-potential study doses. Heavy at 40+ mg based on case report data. Bioavailability ~70% from Ref 27.

Evidence basis: controlled_human_study

sublingualtrace

FieldPublishedAI ProposedConfidence
Threshold1.75 mg1.75 mgmedium
Low1.75–5 mg1.75–5 mgmedium
Common5–10 mg5–10 mgmedium
Strong——medium
Heavy——medium
Editorial

Sublingual formulations include Intermezzo (1.75 mg, 3.5 mg for middle-of-night dosing) and Edluar (5 mg, 10 mg). Roth 2008 (Ref 45) confirmed efficacy of 1.75–3.5 mg sublingual for nocturnal awakenings. Staner 2009 (Ref 17) demonstrated earlier sleep onset with sublingual vs oral 10 mg. Higher recreational dose ranges not separately characterized for sublingual ROA — supratherapeutic sublingual use would overlap with oral dose ranges.

Reasoning

Sublingual formulations include Intermezzo (1.75 mg, 3.5 mg for middle-of-night dosing) and Edluar (5 mg, 10 mg). Roth 2008 (Ref 45) confirmed efficacy of 1.75–3.5 mg sublingual for nocturnal awakenings. Staner 2009 (Ref 17) demonstrated earlier sleep onset with sublingual vs oral 10 mg. Higher recreational dose ranges not separately characterized for sublingual ROA — supratherapeutic sublingual use would overlap with oral dose ranges.

Evidence basis: controlled_human_study

Duration

oral

FieldPublishedAI ProposedConfidence
Onsettrace15–30 minutes15–30 minuteshigh
Editorial

Rapid oral absorption with Tmax 0.75–2.6 hours (Ref 27, Ref 5). First perceptible sedative effects reported within 15–30 minutes of ingestion on an empty stomach. Food delays onset by reducing Cmax ~25% (Ref 36).

Reasoning

Rapid oral absorption with Tmax 0.75–2.6 hours (Ref 27, Ref 5). First perceptible sedative effects reported within 15–30 minutes of ingestion on an empty stomach. Food delays onset by reducing Cmax ~25% (Ref 36).

Evidence basis: controlled_human_study

After effectstrace2–6 hours2–6 hourshigh
Editorial

Residual next-morning impairment documented by FDA 2013 (Ref 25): 15% of women retained blood levels ≥50 ng/mL at 8 hours post-10 mg dose. Kleykamp 2012 (Ref 12) documented persistent cognitive impairment. Aftereffects encompass subtle psychomotor impairment, drowsiness, and cognitive dulling beyond the primary subjective experience.

Reasoning

Residual next-morning impairment documented by FDA 2013 (Ref 25): 15% of women retained blood levels ≥50 ng/mL at 8 hours post-10 mg dose. Kleykamp 2012 (Ref 12) documented persistent cognitive impairment. Aftereffects encompass subtle psychomotor impairment, drowsiness, and cognitive dulling beyond the primary subjective experience.

Evidence basis: controlled_human_study

Come uptrace15–45 minutes15–45 minuteshigh
Editorial

Building sedation from first effects through approaching peak, corresponding to the absorption phase before Tmax. Duration reflects the range between initial perception and peak plasma concentration.

Reasoning

Building sedation from first effects through approaching peak, corresponding to the absorption phase before Tmax. Duration reflects the range between initial perception and peak plasma concentration.

Evidence basis: controlled_human_study

Peaktrace1–2 hours1–2 hourshigh
Editorial

Peak effects centered around Tmax (~1.6 hours median). Duration of maximum subjective intensity approximately 1–2 hours based on the PK profile: rapid rise to Cmax with elimination half-life of 1.5–3.2 hours (Ref 27).

Reasoning

Peak effects centered around Tmax (~1.6 hours median). Duration of maximum subjective intensity approximately 1–2 hours based on the PK profile: rapid rise to Cmax with elimination half-life of 1.5–3.2 hours (Ref 27).

Evidence basis: controlled_human_study

Offsettrace2–3 hours2–3 hourshigh
Editorial

Declining intensity from peak back toward baseline, corresponding to the elimination phase. With half-life 1.5–3.2 hours, subjective effects diminish over approximately 2–3 hours post-peak (Ref 27).

Reasoning

Declining intensity from peak back toward baseline, corresponding to the elimination phase. With half-life 1.5–3.2 hours, subjective effects diminish over approximately 2–3 hours post-peak (Ref 27).

Evidence basis: controlled_human_study

Totaltrace4–7 hours4–7 hourshigh
Editorial

Total subjective experience duration from onset through offset. At therapeutic doses (5–10 mg IR), subjective sedation spans approximately 5–7 hours, consistent with the recommended 7–8 hour sleep window. At supratherapeutic doses, effects may persist longer due to higher plasma levels. Half-life of 1.5–3.2 hours (Ref 27) with ~70% bioavailability supports this range.

Reasoning

Total subjective experience duration from onset through offset. At therapeutic doses (5–10 mg IR), subjective sedation spans approximately 5–7 hours, consistent with the recommended 7–8 hour sleep window. At supratherapeutic doses, effects may persist longer due to higher plasma levels. Half-life of 1.5–3.2 hours (Ref 27) with ~70% bioavailability supports this range.

Evidence basis: controlled_human_study

sublingual

FieldPublishedAI ProposedConfidence
Onsettrace10–20 minutes10–20 minutesmedium
Editorial

Staner 2009 (Ref 17) demonstrated earlier sleep onset with sublingual versus oral zolpidem, attributed to faster absorption and partial avoidance of first-pass metabolism. Onset is faster than oral by approximately 5–10 minutes.

Reasoning

Staner 2009 (Ref 17) demonstrated earlier sleep onset with sublingual versus oral zolpidem, attributed to faster absorption and partial avoidance of first-pass metabolism. Onset is faster than oral by approximately 5–10 minutes.

Evidence basis: controlled_human_study

Totaltrace3–6 hours3–6 hoursmedium
Editorial

Low-dose sublingual (1.75–3.5 mg Intermezzo) is designed for middle-of-night dosing with shorter total duration than oral IR. Higher sublingual doses (5–10 mg Edluar) have comparable duration to oral. Range reflects both formulations.

Reasoning

Low-dose sublingual (1.75–3.5 mg Intermezzo) is designed for middle-of-night dosing with shorter total duration than oral IR. Higher sublingual doses (5–10 mg Edluar) have comparable duration to oral. Range reflects both formulations.

Evidence basis: controlled_human_study

Safety

Toxicity Profiletrace

FieldPublishedAI ProposedConfidence
Acutelowlowhigh
Chronicmoderatemoderatehigh
Organs Affectedcentral_nervous_system, respiratorycentral_nervous_system, respiratoryhigh
Editorial

Acute toxicity classified as low based on StatPearls (Ref 36) characterization of single-drug overdose as benign and Salvà 1995 (Ref 27) comparison to benzodiazepines. Chronic classified as moderate based on Kleykamp 2012 (Ref 12, persistent cognitive impairment), Glass 2005 (Ref 16, falls meta-analysis), and documented dependence with seizures (Wang 2011, Ref 30). Research output explicitly flagged that 'high' acute toxicity in seed data was overstated relative to published evidence.

Reasoning

Acute toxicity classified as low based on StatPearls (Ref 36) characterization of single-drug overdose as benign and Salvà 1995 (Ref 27) comparison to benzodiazepines. Chronic classified as moderate based on Kleykamp 2012 (Ref 12, persistent cognitive impairment), Glass 2005 (Ref 16, falls meta-analysis), and documented dependence with seizures (Wang 2011, Ref 30). Research output explicitly flagged that 'high' acute toxicity in seed data was overstated relative to published evidence.

Evidence basis: systematic_review

Dependence Profiletrace

FieldPublishedAI ProposedConfidence
Physicalmoderatemoderatehigh
Psychologicalmoderatemoderatehigh
Compulsive Redosingmoderatemoderatehigh
Dose Escalationmoderatemoderatehigh
Editorial

Physical dependence documented by Wang 2011 (Ref 30, withdrawal seizures at 200-500 mg/day) and Mao 2022 (Ref 7, withdrawal symptom chronology). Psychological dependence and reinforcement confirmed by Schoedel 2016 (Ref 22, abuse potential RCT) and Heydari 2013 (Ref 10, case report of euphoric abuse). Elderly dependence prevalence from Victorri-Vigneau 2021 (Ref 44). Moderate classification reflects dose-dependent risk: low at therapeutic doses, high at recreational doses.

Reasoning

Physical dependence documented by Wang 2011 (Ref 30, withdrawal seizures at 200-500 mg/day) and Mao 2022 (Ref 7, withdrawal symptom chronology). Psychological dependence and reinforcement confirmed by Schoedel 2016 (Ref 22, abuse potential RCT) and Heydari 2013 (Ref 10, case report of euphoric abuse). Elderly dependence prevalence from Victorri-Vigneau 2021 (Ref 44). Moderate classification reflects dose-dependent risk: low at therapeutic doses, high at recreational doses.

Evidence basis: controlled_human_study

Withdrawal Profiletrace

FieldPublishedAI ProposedConfidence
Severitysevereseverehigh
Symptomsinsomnia, anxiety, restlessness, paresthesia, flu-like symptoms, tremor, tonic seizures, hallucinationsinsomnia, anxiety, restlessness, paresthesia, flu-like symptoms, tremor, tonic seizures, hallucinationshigh
FatalNoNohigh
Medical SupervisionRequiredRequiredhigh
Editorial

Withdrawal documented by Wang 2011 (Ref 30, tonic seizures on abrupt discontinuation from 200-500 mg/day) and Mao 2022 (Ref 7, chronological symptom profile). Severity rated as severe due to seizure risk, though this reflects high-dose chronic use; withdrawal from therapeutic doses is typically milder (rebound insomnia, anxiety). Medical supervision required due to seizure risk.

Reasoning

Withdrawal documented by Wang 2011 (Ref 30, tonic seizures on abrupt discontinuation from 200-500 mg/day) and Mao 2022 (Ref 7, chronological symptom profile). Severity rated as severe due to seizure risk, though this reflects high-dose chronic use; withdrawal from therapeutic doses is typically milder (rebound insomnia, anxiety). Medical supervision required due to seizure risk.

Evidence basis: controlled_human_study

Tolerance Profiletrace

FieldPublishedAI ProposedConfidence
Buildupslowslowhigh
Half-life——high
Full Reset——high
Cross-tolerancesbenzodiazepines, zopiclone, zaleplon, alcoholbenzodiazepines, zopiclone, zaleplon, alcoholhigh
Editorial

Tolerance data from Monti 1994 (Ref 38, no hypnotic tolerance over 27 nights), Kleykamp 2012 (Ref 12, no cognitive tolerance over 1 month), Wang 2011 (Ref 30, tolerance at high doses), and Jembrek 2015 (Ref 4, molecular mechanism). Cross-tolerance with benzodiazepines is expected due to shared BZ binding site; Wright 2014 (Ref 9) demonstrated comparable tolerance/withdrawal profiles between zolpidem and diazepam in mice.

Reasoning

Tolerance data from Monti 1994 (Ref 38, no hypnotic tolerance over 27 nights), Kleykamp 2012 (Ref 12, no cognitive tolerance over 1 month), Wang 2011 (Ref 30, tolerance at high doses), and Jembrek 2015 (Ref 4, molecular mechanism). Cross-tolerance with benzodiazepines is expected due to shared BZ binding site; Wright 2014 (Ref 9) demonstrated comparable tolerance/withdrawal profiles between zolpidem and diazepam in mice.

Evidence basis: controlled_human_study

Effects & Profile

Contraindications

FieldPublishedAI ProposedConfidence
other known hypersensitivity to zolpidemtraceabsoluteabsolutehigh
Editorial

Standard pharmacovigilance contraindication; listed in FDA prescribing information (Ref 36).

Reasoning

Standard pharmacovigilance contraindication; listed in FDA prescribing information (Ref 36).

neurological prior complex sleep behaviors on zolpidemtraceabsoluteabsolutehigh
Editorial

FDA boxed warning based on FAERS data (Ref 11, Wong 2017) and case reports (Ref 31, Paulke 2015). Complex sleep behaviors documented at therapeutic doses.

Reasoning

FDA boxed warning based on FAERS data (Ref 11, Wong 2017) and case reports (Ref 31, Paulke 2015). Complex sleep behaviors documented at therapeutic doses.

hepatic severe hepatic impairmenttraceabsoluteabsolutehigh
Editorial

Pharmacokinetic basis from Salvà 1995 (Ref 27) and StatPearls (Ref 36). Sharma 2019 (Ref 47) demonstrated safe use in cirrhosis only at reduced doses with monitoring.

Reasoning

Pharmacokinetic basis from Salvà 1995 (Ref 27) and StatPearls (Ref 36). Sharma 2019 (Ref 47) demonstrated safe use in cirrhosis only at reduced doses with monitoring.

respiratory severe respiratory insufficiencytracerelativerelativehigh
Editorial

Respiratory depression documented in overdose (Ref 6, Lheureux 1990) and in combination with CNS depressants (Ref 37). StatPearls lists as precaution (Ref 36).

Reasoning

Respiratory depression documented in overdose (Ref 6, Lheureux 1990) and in combination with CNS depressants (Ref 37). StatPearls lists as precaution (Ref 36).

respiratory obstructive sleep apneatracerelativerelativemedium
Editorial

Research output notes relative contraindication. OSA data limited; not a strong evidence base but mechanism supports caution.

Reasoning

Research output notes relative contraindication. OSA data limited; not a strong evidence base but mechanism supports caution.

neurological myasthenia gravistracerelativerelativemedium
Editorial

Class-level contraindication for GABAergic agents; not specific to zolpidem. Set as relative with medium confidence.

Reasoning

Class-level contraindication for GABAergic agents; not specific to zolpidem. Set as relative with medium confidence.

psychiatric active substance use disordertracerelativerelativehigh
Editorial

Abuse potential confirmed by Schoedel 2016 (Ref 22, RCT in recreational users) and case reports of extreme dependence (Ref 30, Wang 2011; Ref 10, Heydari 2013).

Reasoning

Abuse potential confirmed by Schoedel 2016 (Ref 22, RCT in recreational users) and case reports of extreme dependence (Ref 30, Wang 2011; Ref 10, Heydari 2013).

pregnancy breastfeeding pregnancytracerelativerelativehigh
Editorial

StatPearls (Ref 36) documents placental crossing and neonatal respiratory depression risk.

Reasoning

StatPearls (Ref 36) documents placental crossing and neonatal respiratory depression risk.

pregnancy breastfeeding breastfeedingtracerelativerelativehigh
Editorial

StatPearls (Ref 36) documents breast milk excretion and recommends temporary cessation.

Reasoning

StatPearls (Ref 36) documents breast milk excretion and recommends temporary cessation.

age elderlytracerelativerelativehigh
Editorial

Glass 2005 (Ref 16, meta-analysis of fall risk), Sateia 2017 (Ref 15, AASM guidelines), Schroeck 2016 (Ref 48, elderly safety review), Assimon 2020 (Ref 40, fracture risk in hemodialysis). Well-documented with high-quality evidence.

Reasoning

Glass 2005 (Ref 16, meta-analysis of fall risk), Sateia 2017 (Ref 15, AASM guidelines), Schroeck 2016 (Ref 48, elderly safety review), Assimon 2020 (Ref 40, fracture risk in hemodialysis). Well-documented with high-quality evidence.

age pediatric usetraceabsoluteabsolutehigh
Editorial

StatPearls (Ref 36) notes not approved in pediatrics, hallucinations reported, and higher clearance rates.

Reasoning

StatPearls (Ref 36) notes not approved in pediatrics, hallucinations reported, and higher clearance rates.

Timeline Phases

oral

FieldPublishedAI ProposedConfidence
Onsettrace900–1800 sec(i=0.05)900–1800 sec(i=0.05)high
Editorial

Timeline derived from well-characterized PK parameters: Tmax ~1.6h (Ref 27, Ref 5), half-life 1.5–3.2h (Ref 27), and FDA 2013 data showing 15% of women retain impairment-level blood concentrations at 8 hours (Ref 25). Sleep architecture data from Refs 32, 42 inform the peak/plateau phases. Afterglow impairment documented by Kleykamp 2012 (Ref 12) and FDA safety communications.

Reasoning

Timeline derived from well-characterized PK parameters: Tmax ~1.6h (Ref 27, Ref 5), half-life 1.5–3.2h (Ref 27), and FDA 2013 data showing 15% of women retain impairment-level blood concentrations at 8 hours (Ref 25). Sleep architecture data from Refs 32, 42 inform the peak/plateau phases. Afterglow impairment documented by Kleykamp 2012 (Ref 12) and FDA safety communications.

Evidence basis: controlled_human_study

Come uptrace900–1800 sec(i=0.30)900–1800 sec(i=0.30)high
Editorial

Timeline derived from well-characterized PK parameters: Tmax ~1.6h (Ref 27, Ref 5), half-life 1.5–3.2h (Ref 27), and FDA 2013 data showing 15% of women retain impairment-level blood concentrations at 8 hours (Ref 25). Sleep architecture data from Refs 32, 42 inform the peak/plateau phases. Afterglow impairment documented by Kleykamp 2012 (Ref 12) and FDA safety communications.

Reasoning

Timeline derived from well-characterized PK parameters: Tmax ~1.6h (Ref 27, Ref 5), half-life 1.5–3.2h (Ref 27), and FDA 2013 data showing 15% of women retain impairment-level blood concentrations at 8 hours (Ref 25). Sleep architecture data from Refs 32, 42 inform the peak/plateau phases. Afterglow impairment documented by Kleykamp 2012 (Ref 12) and FDA safety communications.

Evidence basis: controlled_human_study

Peaktrace3600–7200 sec(i=1.00)3600–7200 sec(i=1.00)high
Editorial

Timeline derived from well-characterized PK parameters: Tmax ~1.6h (Ref 27, Ref 5), half-life 1.5–3.2h (Ref 27), and FDA 2013 data showing 15% of women retain impairment-level blood concentrations at 8 hours (Ref 25). Sleep architecture data from Refs 32, 42 inform the peak/plateau phases. Afterglow impairment documented by Kleykamp 2012 (Ref 12) and FDA safety communications.

Reasoning

Timeline derived from well-characterized PK parameters: Tmax ~1.6h (Ref 27, Ref 5), half-life 1.5–3.2h (Ref 27), and FDA 2013 data showing 15% of women retain impairment-level blood concentrations at 8 hours (Ref 25). Sleep architecture data from Refs 32, 42 inform the peak/plateau phases. Afterglow impairment documented by Kleykamp 2012 (Ref 12) and FDA safety communications.

Evidence basis: controlled_human_study

Plateautrace3600–5400 sec(i=0.50)3600–5400 sec(i=0.50)high
Editorial

Timeline derived from well-characterized PK parameters: Tmax ~1.6h (Ref 27, Ref 5), half-life 1.5–3.2h (Ref 27), and FDA 2013 data showing 15% of women retain impairment-level blood concentrations at 8 hours (Ref 25). Sleep architecture data from Refs 32, 42 inform the peak/plateau phases. Afterglow impairment documented by Kleykamp 2012 (Ref 12) and FDA safety communications.

Reasoning

Timeline derived from well-characterized PK parameters: Tmax ~1.6h (Ref 27, Ref 5), half-life 1.5–3.2h (Ref 27), and FDA 2013 data showing 15% of women retain impairment-level blood concentrations at 8 hours (Ref 25). Sleep architecture data from Refs 32, 42 inform the peak/plateau phases. Afterglow impairment documented by Kleykamp 2012 (Ref 12) and FDA safety communications.

Evidence basis: controlled_human_study

Resolutiontrace3600–5400 sec(i=0.20)3600–5400 sec(i=0.20)high
Editorial

Timeline derived from well-characterized PK parameters: Tmax ~1.6h (Ref 27, Ref 5), half-life 1.5–3.2h (Ref 27), and FDA 2013 data showing 15% of women retain impairment-level blood concentrations at 8 hours (Ref 25). Sleep architecture data from Refs 32, 42 inform the peak/plateau phases. Afterglow impairment documented by Kleykamp 2012 (Ref 12) and FDA safety communications.

Reasoning

Timeline derived from well-characterized PK parameters: Tmax ~1.6h (Ref 27, Ref 5), half-life 1.5–3.2h (Ref 27), and FDA 2013 data showing 15% of women retain impairment-level blood concentrations at 8 hours (Ref 25). Sleep architecture data from Refs 32, 42 inform the peak/plateau phases. Afterglow impairment documented by Kleykamp 2012 (Ref 12) and FDA safety communications.

Evidence basis: controlled_human_study

Afterglowtrace7200–14400 sec(i=0.05)7200–14400 sec(i=0.05)high
Editorial

Timeline derived from well-characterized PK parameters: Tmax ~1.6h (Ref 27, Ref 5), half-life 1.5–3.2h (Ref 27), and FDA 2013 data showing 15% of women retain impairment-level blood concentrations at 8 hours (Ref 25). Sleep architecture data from Refs 32, 42 inform the peak/plateau phases. Afterglow impairment documented by Kleykamp 2012 (Ref 12) and FDA safety communications.

Reasoning

Timeline derived from well-characterized PK parameters: Tmax ~1.6h (Ref 27, Ref 5), half-life 1.5–3.2h (Ref 27), and FDA 2013 data showing 15% of women retain impairment-level blood concentrations at 8 hours (Ref 25). Sleep architecture data from Refs 32, 42 inform the peak/plateau phases. Afterglow impairment documented by Kleykamp 2012 (Ref 12) and FDA safety communications.

Evidence basis: controlled_human_study

Dose Tier Summaries

thresholdtrace
high

At the threshold dose range (~5 mg oral), effects are subtle and primarily sedative: mild drowsiness, slight relaxation of muscle tension, and a gentle slowing of thought. The experience is easily mistaken for ordinary tiredness. No perceptual changes or mood elevation occur at this level. Physically, mild heaviness in the limbs and slight motor coordination reduction may be noticeable. These effects represent the low end of the FDA-approved therapeutic range. Sleep onset is facilitated but not forced; the experience is manageable and functional impairment is minimal if the individual remains awake, though driving and operating machinery are contraindicated.

Editorial

5 mg is the FDA-approved lower therapeutic dose (women, elderly). Effects at this level are well-characterized in clinical trials as mild sedation and sleep facilitation. Ref 36 (StatPearls), Ref 27 (Salvà 1995), and FDA labeling provide the evidence base.

Reasoning

5 mg is the FDA-approved lower therapeutic dose (women, elderly). Effects at this level are well-characterized in clinical trials as mild sedation and sleep facilitation. Ref 36 (StatPearls), Ref 27 (Salvà 1995), and FDA labeling provide the evidence base.

Evidence basis: controlled_human_study

lighttrace
high

At light doses (5–10 mg oral), sedation becomes the dominant effect. Drowsiness intensifies, thought deceleration is noticeable, and a sense of cognitive slowing sets in. Mild anxiolysis may accompany the sedative effect. Motor coordination is impaired — reaction times slow and fine motor control degrades. Anterograde amnesia begins to emerge, particularly for events occurring after dosing. Physically, muscle relaxation is apparent and eyelid heaviness becomes pronounced. Balance may be subtly affected. This range encompasses the standard FDA-approved therapeutic doses (5–10 mg IR). Sleep onset latency is significantly reduced. If the individual remains awake, functional impairment is moderate — judgment and self-assessment of intoxication are already compromised.

Editorial

5–10 mg is the well-characterized therapeutic dose range. Cognitive effects, amnesia, and psychomotor impairment at these doses are documented in multiple RCTs including Kleykamp 2012 (Ref 12) and Terzano 2003 (Ref 33). Morning-after impairment data from FDA 2013 (Ref 25) further characterize this range.

Reasoning

5–10 mg is the well-characterized therapeutic dose range. Cognitive effects, amnesia, and psychomotor impairment at these doses are documented in multiple RCTs including Kleykamp 2012 (Ref 12) and Terzano 2003 (Ref 33). Morning-after impairment data from FDA 2013 (Ref 25) further characterize this range.

Evidence basis: controlled_human_study

commontrace
medium

At common recreational doses (10–20 mg oral), effects extend beyond sedation into a distinctive altered state. Euphoria emerges alongside pronounced sedation. Cognitive disconnection intensifies — thought processes become disorganized and dreamlike. Anterograde amnesia is prominent; events during this period may not be recalled. Delusions of sobriety are characteristic: users frequently believe they are functioning normally despite obvious impairment. Physically, motor coordination is significantly degraded. Slurred speech, unsteady gait, and difficulty with fine motor tasks are typical. Muscle relaxation is pronounced. Complex sleep behaviors (sleepwalking, sleep-eating) become more likely at this range. Functional impairment is substantial — the individual should not attempt any task requiring coordination or judgment. Duration of noticeable effects extends to 4–6 hours.

Editorial

10–20 mg spans the upper therapeutic dose through 2× the maximum recommended dose. Schoedel 2016 (Ref 22) documented euphoria and cognitive effects beginning at 15 mg in recreational polydrug users. Complex sleep behaviors are documented at therapeutic doses and above (Ref 11, Ref 31). The lower end of this range overlaps clinical use; the upper end enters recreational territory.

Reasoning

10–20 mg spans the upper therapeutic dose through 2× the maximum recommended dose. Schoedel 2016 (Ref 22) documented euphoria and cognitive effects beginning at 15 mg in recreational polydrug users. Complex sleep behaviors are documented at therapeutic doses and above (Ref 11, Ref 31). The lower end of this range overlaps clinical use; the upper end enters recreational territory.

Evidence basis: controlled_human_study

strongtrace
medium

At strong doses (20–40 mg oral), the experience shifts markedly into recreational/hallucinogenic territory. Pronounced euphoria, visual and auditory hallucinations, and perceptual distortions dominate. Thought disorganization becomes severe — coherent reasoning is largely suspended. Time distortion is prominent. The dreamlike hypnagogic quality intensifies, with open-eye visual disturbances and vivid internal imagery. Delusions of sobriety persist despite profound impairment. Physically, severe motor incoordination, slurred speech, and loss of balance are expected. Respiratory rate may decrease modestly. Nausea is possible. Amnesia for the entire experience is common. Risk of complex sleep behaviors, accidental injury, and self-harm through impaired judgment is high. This dose range exceeds approved use by 2–4× and carries significant safety risk, particularly in combination with any other CNS depressant.

Editorial

Schoedel 2016 (Ref 22) administered 30 mg to recreational users and documented dose-dependent hallucinations, euphoria, and elevated Bowdle VAS (psychedelic-type) scores. Case reports describe effects at these doses. This range is 2–4× the maximum therapeutic dose.

Reasoning

Schoedel 2016 (Ref 22) administered 30 mg to recreational users and documented dose-dependent hallucinations, euphoria, and elevated Bowdle VAS (psychedelic-type) scores. Case reports describe effects at these doses. This range is 2–4× the maximum therapeutic dose.

Evidence basis: controlled_human_study

heavytrace
medium

At heavy doses (40+ mg oral), zolpidem produces extreme sedation, profound hallucinations, and near-complete cognitive dissolution. Consciousness may fluctuate between agitated delirium and deep sedation. Complete amnesia is universal. Behavior becomes unpredictable — complex automatisms (walking, talking, driving) may occur without any subsequent memory. At doses exceeding 100 mg, frank psychotic features including paranoid ideation and bizarre behavior have been reported. Physically, respiratory depression becomes a clinical concern, particularly in combination with alcohol or opioids. Profound motor incapacitation, potential loss of consciousness, and aspiration risk are present. Cardiac monitoring may be warranted. This range represents dangerous recreational misuse. Case reports document chronic use at 200–500 mg/day, which produces severe physical dependence with seizure risk on abrupt discontinuation. Any dose in this range carries risk of serious medical emergency, particularly without tolerance.

Editorial

Wang et al. 2011 (Ref 30) documented patients using 200–500 mg/day. Heydari 2013 (Ref 10) documented euphoric abuse patterns. Lheureux 1990 (Ref 6) documented coma and respiratory depression in overdose. Effects at this range are inferred from overdose case reports and extreme recreational use cases. No controlled studies have administered doses above 30 mg.

Reasoning

Wang et al. 2011 (Ref 30) documented patients using 200–500 mg/day. Heydari 2013 (Ref 10) documented euphoric abuse patterns. Lheureux 1990 (Ref 6) documented coma and respiratory depression in overdose. Effects at this range are inferred from overdose case reports and extreme recreational use cases. No controlled studies have administered doses above 30 mg.

Evidence basis: published_case_series

02

History

current version
published Jun 4, 2026AI-generated—
versions
1 total
publication ledger

backfill Jun 4, 2026

Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.

full version history suggest a correctioncontact@psychedex.org
03

Sources

18 strong · 21 moderate · 8 weak
  1. [1]
    moderate
    Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications
    Salva P, Costa J · 1995 · Clinical Pharmacokinetics
    pubmed 852167719 claims checked6 verified1 partial12 inconclusive
  2. [2]
    moderate
    Zolpidem for insomnia
    Greenblatt DJ, Roth T · 2012 · Expert Opinion on Pharmacotherapy
    doi.org/10.1517/14656566.2012.667074pubmed 224245862 claims checked1 verified1 inconclusive
  3. [3]
    weak
    FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, Zolpimist)
    US Food and Drug Administration · 2013
    linkno claims checked
  4. [4]
    moderate
    Structural and dynamic mechanisms of GABAA receptor modulators with opposing activities
    Zhu S, Sridhar A, Teng J, Howard RJ, Lindahl E, Hibbs RE · 2022 · Nature Communications
    doi.org/10.1038/s41467-022-32212-4pubmed 359334263 claims checked2 verified1 inconclusive
  5. [5]
    moderate
    Probing the molecular basis for affinity/potency- and efficacy-based subtype-selectivity exhibited by benzodiazepine-site modulators at GABAA receptors
    Soderhielm PC, Balle T, Bak-Nyhus S, Zhang M, Hansen KM, Ahring PK, Jensen AA · 2018 · Biochemical Pharmacology
    doi.org/10.1016/j.bcp.2018.08.019pubmed 301212485 claims checked4 verified1 inconclusive
  6. [6]
    strong
    Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study
    Schoedel KA, Sun H, Sellers EM, et al. · 2016 · Journal of Clinical Psychopharmacology
    doi.org/10.1097/jcp.0000000000000516pubmed 272536586 claims checked2 verified4 inconclusive
  7. [7]
    moderate
    Spontaneous Adverse Event Reports Associated with Zolpidem in the United States 2003-2012
    Wong CK, Marshall NS, Grunstein RR, et al. · 2017 · Journal of Clinical Sleep Medicine
    doi.org/10.5664/jcsm.6452pubmed 277844182 claims checked2 inconclusive
  8. [8]
    weak
    Zolpidem intoxication mimicking narcotic overdose: response to flumazenil
    Lheureux P, Debailleul G, De Witte O, Askenasi R · 1990 · Human & Experimental Toxicology
    pubmed 21111566 claims checked6 verified
  9. [9]
    strong
    Zolpidem and rebound insomnia--a double-blind, controlled polysomnographic study in chronic insomniac patients
    Monti JM, Attali P, Monti D, Zipfel A, de la Giclais B, Morselli PL · 1994 · Pharmacopsychiatry
    pubmed 79723494 claims checked3 verified1 partial
  10. [10]
    strong
    Acute effects of zolpidem extended-release on cognitive performance and sleep in healthy males after repeated nightly use
    Kleykamp BA, Griffiths RR, McCann UD, Smith MT, Mintzer MZ · 2012 · Experimental and Clinical Psychopharmacology
    doi.org/10.1037/a0025237pubmed 219289136 claims checked6 verified
  11. [11]
    weak
    Zolpidem dependence and withdrawal seizure--report of two cases
    Wang LJ, Ree SC, Chu CL, Juang YY · 2011 · Psychiatria Danubina
    pubmed 214481026 claims checked3 verified1 partial2 inconclusive
  12. [12]
    moderate
    Zolpidem withdrawal induced uncoupling of GABA(A) receptors in vitro associated with altered GABA(A) receptor subunit mRNA expression
    Jembrek MJ, Vlainic J, Suran J · 2015 · Acta Neurobiologiae Experimentalis
    doi.org/10.55782/ane-2015-2025pubmed 262329932 claims checked1 verified1 inconclusive
  13. [13]
    moderate
    Regional differences in the inhibition of mouse in vivo [3H]Ro 15-1788 binding reflect selectivity for alpha1 versus alpha2 and alpha3 subunit-containing GABAA receptors
    Atack JR, Smith AJ, Emms F, McKernan RM · 1999 · Neuropsychopharmacology
    pubmed 100634854 claims checked4 verified
  14. [14]
    moderate
    New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon
    Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L · 2003 · Drug Safety
    pubmed 126088885 claims checked4 verified1 inconclusive
  15. [15]
    moderate
    Zolpidem and eszopiclone prime a1b2g2 GABAA receptors for longer duration of activity
    Dixon CL, Harrison NL, Lynch JW, Keramidas A · 2015 · British Journal of Pharmacology
    doi.org/10.1111/bph.13142pubmed 258173201 claim checked1 verified
  16. [16]
    moderate
    Silencing the brain may be better than stimulating it. The GABA effect
    Pistoia F, Sara M, Sacco S, Franceschini M, Carolei A · 2014 · Current Pharmaceutical Design
    pubmed 240250662 claims checked2 verified
  17. [17]
    strong
    Comparative bioavailability of two zolpidem hemitartrate formulations in healthy human Brazilian volunteers
    Mendes GD, Pereira TDS, Rodrigues JC, et al. · 2020 · Biomedical Chromatography
    doi.org/10.1002/bmc.4731pubmed 316523444 claims checked1 verified2 partial1 inconclusive
  18. [18]
    moderate
    Sex differences in pharmacokinetics predict adverse drug reactions in women
    Zucker I, Prendergast BJ · 2020 · Biology of Sex Differences
    doi.org/10.1186/s13293-020-00308-5pubmed 325036372 claims checked2 inconclusive
  19. [19]
    weak
    Zolpidem - StatPearls
    Singh D, Saadabadi A · 2024
    linkno claims checked
  20. [20]
    strong
    Relationship between plasma exposure of zolpidem and CYP2D6 genotype in healthy Korean subjects
    Jung EH, Lee CM, Byeon JY, et al. · 2020 · Archives of Pharmacal Research
    doi.org/10.1007/s12272-020-01250-1pubmed 326619203 claims checked1 verified2 inconclusive
  21. [21]
    moderate
    Examination of Zolpidem effects on AhR- and PXR-dependent expression of drug-metabolizing cytochromes P450 in primary cultures of human hepatocytes
    Bachleda P, Vrzal R, Pivnicka J, Cvek B, Dvorak Z · 2009 · Toxicology Letters
    doi.org/10.1016/j.toxlet.2009.08.009pubmed 196868242 claims checked2 verified
  22. [22]
    strong
    Effects on sleep stages and microarchitecture of caffeine and its combination with zolpidem or trazodone in healthy volunteers
    Paterson LM, Nutt DJ, Ivarsson M, Hutson PH, Wilson SJ · 2009 · Journal of Psychopharmacology
    doi.org/10.1177/0269881109104852pubmed 193518012 claims checked1 verified1 partial
  23. [23]
    strong
    Independence of sleep EEG responses to GABAergic hypnotics: biological implications
    Palagini L, Campbell IG, Tan X, Guazzelli M, Feinberg I · 2000 · Journal of Psychiatric Research
    pubmed 111048412 claims checked1 verified1 partial
  24. [24]
    weak
    Zolpidem dependence, abuse and withdrawal: A case report
    Heydari M, Isfeedvajani MS · 2013 · Journal of Research in Medical Sciences
    pubmed 24520235no claims checked
  25. [25]
    moderate
    Zolpidem extended-release
    Moen MD, Plosker GL · 2006 · CNS Drugs
    pubmed 166965811 claim checked1 verified
  26. [26]
    strong
    Sublingual zolpidem is more effective than oral zolpidem in initiating early onset of sleep
    Staner L, Eriksson M, Cornette F, et al. · 2009 · Sleep Medicine
    doi.org/10.1016/j.sleep.2008.06.008pubmed 189967422 claims checked2 verified
  27. [27]
    strong
    Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night awakenings
    Roth T, Hull SG, Lankford DA, Rosenberg R, Scharf MB · 2008 · Sleep
    pubmed 187886532 claims checked2 verified
  28. [28]
    strong
    Drug interaction between St John's wort and zolpidem in healthy subjects
    Hojo Y, Echizenya M, Ohkubo T, Shimizu T · 2011 · Journal of Clinical Pharmacy and Therapeutics
    doi.org/10.1111/j.1365-2710.2010.01223.xpubmed 210589682 claims checked2 verified
  29. [29]
    moderate
    Review of Safety and Efficacy of Sleep Medicines in Older Adults
    Schroeck JL, Ford J, Conway EL, et al. · 2016 · Clinical Therapeutics
    doi.org/10.1016/j.clinthera.2016.09.010pubmed 277516691 claim checked1 inconclusive
  30. [30]
    strong
    Effects of zolpidem on sleep parameters in patients with cirrhosis and sleep disturbances: A randomized, placebo-controlled trial
    Sharma MK, Kainth S, Kumar S, et al. · 2019 · Clinical and Molecular Hepatology
    doi.org/10.3350/cmh.2018.0084pubmed 308566891 claim checked1 inconclusive
  31. [31]
    strong
    Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.
    Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL · 2017 · Journal of Clinical Sleep Medicine
    doi.org/10.5664/jcsm.6470pubmed 279983792 claims checked2 inconclusive
  32. [32]
    moderate
    The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023
    Riemann D, Espie CA, Altena E, et al. · 2023 · Journal of Sleep Research
    doi.org/10.1111/jsr.14035pubmed 380164841 claim checked1 verified
  33. [33]
    strong
    Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation
    Dundar Y, Boland A, Strobl J, et al. · 2004 · Health Technology Assessment
    pubmed 151932092 claims checked2 inconclusive
  34. [34]
    strong
    Comparison of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults
    Moline M, Zammit G, Cheng JY, et al. · 2021 · Journal of Clinical Sleep Medicine
    doi.org/10.5664/jcsm.9150pubmed 335908232 claims checked2 inconclusive
  35. [35]
    strong
    The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer's disease: a randomized, triple-blind, placebo-controlled trial
    Louzada LL, Machado FV, Quintas JL, et al. · 2022 · Neuropsychopharmacology
    doi.org/10.1038/s41386-021-01191-3pubmed 34635802no claims checked
  36. [36]
    strong
    Comparison of the treatment effectiveness between lemborexant and zolpidem tartrate extended-release for insomnia disorder subtypes
    Inoue Y, Nishida M, Kubota N, et al. · 2023 · Journal of Clinical Sleep Medicine
    doi.org/10.5664/jcsm.10378pubmed 364721341 claim checked1 verified
  37. [37]
    strong
    Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
    Glass JR, Lanctot KL, Herrmann N, Sproule B, Busto UE · 2005 · BMJ
    doi.org/10.1136/bmj.38623.768588.47pubmed 162842082 claims checked2 verified
  38. [38]
    moderate
    Benzodiazepines and Z-Drugs: An Updated Review of Major Adverse Outcomes Reported on in Epidemiologic Research
    Brandt J, Leong C · 2017 · Drugs in R&D
    doi.org/10.1007/s40268-017-0207-7pubmed 288650382 claims checked2 verified
  39. [39]
    moderate
    Zolpidem Versus Trazodone Initiation and the Risk of Fall-Related Fractures among Individuals Receiving Maintenance Hemodialysis
    Assimon MM, Flythe JE · 2020 · Clinical Journal of the American Society of Nephrology
    doi.org/10.2215/cjn.10070620pubmed 333551921 claim checked1 inconclusive
  40. [40]
    moderate
    Association Between Z Drugs Use and Risk of Cognitive Impairment in Middle-Aged and Older Patients With Chronic Insomnia
    Guo F, Yi L, Zhang W, et al. · 2021 · Frontiers in human neuroscience
    doi.org/10.3389/fnhum.2021.775144pubmed 349557921 claim checked1 verified
  41. [41]
    weak
    Sleep self-intoxication and sleep driving as rare zolpidem-induced complex behaviour
    Paulke A, Wunder C, Toennes SW · 2015 · International Journal of Legal Medicine
    doi.org/10.1007/s00414-014-0997-xpubmed 247704721 claim checked1 verified
  42. [42]
    moderate
    The effects of repeated zolpidem treatment on tolerance, withdrawal-like symptoms, and GABAA receptor mRNAs profile expression in mice: comparison with diazepam
    Wright BT, Gluszek CF, Heldt SA · 2014 · Psychopharmacology
    doi.org/10.1007/s00213-014-3473-xpubmed 245315682 claims checked2 verified
  43. [43]
    weak
    Case report: Chronological symptom profile after cessation of overdose zolpidem in a patient with comorbid bipolar disorder
    Mao ZX, Yang X, Wang HY, Guo WJ · 2022 · Frontiers in Psychiatry
    doi.org/10.3389/fpsyt.2022.962836pubmed 360612921 claim checked1 verified
  44. [44]
    moderate
    Are Seniors Dependent on Benzodiazepines? A National Clinical Survey of Substance Use Disorder
    Victorri-Vigneau C, Laforgue EJ, Grall-Bronnec M, et al. · 2021 · Clinical Pharmacology and Therapeutics
    doi.org/10.1002/cpt.2025pubmed 328604241 claim checked1 verified
  45. [45]
    weak
    HPLC quantification of zolpidem and prothipendyl in a voluntary intoxication
    Debailleul G, Khalil FA, Lheureux P · 1991 · Journal of Analytical Toxicology
    pubmed 16752982 claims checked2 verified
  46. [46]
    moderate
    Comparative tolerability of newer agents for insomnia
    Zammit G · 2009 · Drug Safety
    doi.org/10.2165/11312920-000000000-00000pubmed 19670914no claims checked
  47. [47]
    strong
    Efficacy and safety of insomnia pharmacotherapies: Convergent evidence from Bayesian network meta-regression and FAERS-based disproportionality analysis
    Liu H, Wang Y, Li M, et al. · 2025 · Sleep Medicine
    doi.org/10.1016/j.sleep.2025.106848pubmed 411011481 claim checked1 verified
04

Claim Verification

Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.

summary11 claims7verified1partial3inconclusive
verifiedPhysical dependence with withdrawal seizures is documented at high doses (200–500 mg/day)[11]model confidence 97%
Verified

The abstract directly confirms two cases with doses of 200–400 mg/night and 400–500 mg/day, with tonic seizures on abrupt discontinuation.

Two cases: doses 200-400 mg/night and 400-500 mg/day for euphoria. Abrupt discontinuation produced anxiety, insomnia, restlessness, tonic seizure.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveWith an elimination half-life of 1.5–3.2 hours and oral bioavailability of approximately 70%, it sits at the short-acting end of the sedative-hypnotic spectrum, producing sleep onset within 30–90 minutes at therapeutic doses of 5–10 mg oral.[1]model confidence 72%
Inconclusive

The abstract confirms t1/2 1.5–3.2h and bioavailability ~70%, but does not mention sleep onset timing (30–90 min) or the specific therapeutic doses of 5–10 mg. These clinical claims may be in the full text of this PK/PD review but cannot be verified from the abstract alone.

Bioavailability ~70%, protein binding 92%, t1/2 1.5-3.2h, Tmax 0.75-2.6h after 20mg.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveSynthesized at Synthelabo (Paris) and first approved in Europe in 1988 as Stilnox, zolpidem received FDA approval in 1992 as Ambien and became the most widely prescribed hypnotic in the United States by the early 2000s[2]model confidence 65%
Inconclusive

The abstract confirms zolpidem is the most widely prescribed hypnotic in the US, but does not mention Synthelabo, Paris, the 1988 European approval, the 1992 FDA approval, or the Stilnox/Ambien brand names. These historical specifics are not verifiable from the abstract.

Zolpidem (imidazopyridine) is most widely prescribed hypnotic in US.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedZolpidem's pharmacological signature is strong preferential affinity for α1 subunit-containing GABA-A receptors (BZ₁/omega-1), confirmed by cryo-EM structural work and traced to a single residue — Gly201 on the α1 subunit versus Glu225 on α3[4]model confidence 78%
Verified

The abstract confirms high-resolution structural work revealing the basis for zolpidem's subtype selectivity, supporting the structural confirmation aspect of the claim. The specific residue (Gly201/Glu225) comes from a companion citation; the structural work referenced here confirms selectivity at the α/γ interface.

Structural analyses reveal basis for subtype selectivity of zolpidem.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedZolpidem's pharmacological signature is strong preferential affinity for α1 subunit-containing GABA-A receptors (BZ₁/omega-1), confirmed by cryo-EM structural work and traced to a single residue — Gly201 on the α1 subunit versus Glu225 on α3[5]model confidence 95%
Verified

The abstract directly confirms that substitution of Gly201 in α1 with Glu (as in α3) completely eliminated zolpidem's α1-over-α3 preference, precisely matching the claim's residue-level attribution.

Substitution of Gly201 in a1 with Glu in a3 completely eliminated zolpidem's a1-over-a3 preference.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedAt supratherapeutic doses (≥15 mg), euphoria, hallucinations, and perceptual distortions emerge dose-dependently[6]model confidence 95%
Verified

The abstract directly confirms that zolpidem at 15 and 30 mg produced dose-related effects on 'high' VAS, euphoric mood, and hallucination in recreational polydrug users.

Zolpidem at 15 and 30mg produced dose-related effects on 'high' VAS, euphoric mood, and hallucination in recreational polydrug users.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveComplex sleep behaviors — sleepwalking, sleep-driving, sleep-eating — occur in susceptible individuals even at prescribed doses, typically with complete amnesia[7]model confidence 65%
Inconclusive

The abstract confirms this is an FDA adverse event analysis for complex neuropsychiatric sleep behaviors with zolpidem, but does not enumerate specific behaviors (sleepwalking, sleep-driving, sleep-eating) or confirm they occur at prescribed doses with complete amnesia. These details would be in the full text.

FDA adverse event analysis for complex neuropsychiatric sleep behaviors with zolpidem 2003-2012.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedSingle-agent acute toxicity is low; overdose presents as short-lasting coma reversible by flumazenil[8]model confidence 90%
Verified

The abstract confirms profound but short-lasting coma reversed dramatically by flumazenil in the first reported zolpidem poisoning case, directly supporting both the short-lasting and flumazenil-reversible aspects of the claim.

Profound but short-lasting coma, pinpoint pupils, respiratory depression. Not reversed by naloxone; dramatically reversed by flumazenil.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialTolerance to hypnotic effects does not develop over 27 nights at therapeutic doses, yet tolerance to cognitive and psychomotor impairments during nighttime awakening also fails to develop — producing persistent functional impairment throughout treatment[9]model confidence 80%
Partial

The abstract confirms no tolerance to hypnotic effect over 27 nights. However, it does not address cognitive or psychomotor impairments during nighttime awakening — that second clause is not supported by this abstract and requires citation [12] for verification.

27-night RCT: zolpidem 10mg vs triazolam 0.5mg vs placebo. Zolpidem effective; no rebound insomnia on withdrawal (unlike triazolam); no tolerance detected.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedTolerance to hypnotic effects does not develop over 27 nights at therapeutic doses, yet tolerance to cognitive and psychomotor impairments during nighttime awakening also fails to develop — producing persistent functional impairment throughout treatment[10]model confidence 95%
Verified

The abstract directly confirms both parts of the claim: ZOL 12.5 mg impairs psychomotor function, attention, working memory, and episodic memory during nighttime awakening, and no tolerance to these performance impairments develops after ~1 month of nightly use.

ZOL 12.5mg impairs psychomotor function, attention, working memory, episodic memory during nighttime awakening. No tolerance to performance impairment after ~1 month nightly use.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe molecular mechanism involves functional uncoupling of GABA and benzodiazepine binding sites rather than receptor downregulation[12]model confidence 85%
Verified

The abstract confirms functional uncoupling between GABA and benzodiazepine binding sites, and shows receptor upregulation (not downregulation) occurring during withdrawal. This is consistent with the claim that uncoupling — rather than downregulation — is the primary mechanism.

Chronic zolpidem treatment and withdrawal induced functional uncoupling between GABA and benzodiazepine binding sites; receptor upregulation and subunit mRNA changes after 96h withdrawal.

checked by claude-sonnet-4-6 · Apr 28, 2026

history1 claim1verified
verifiedBy the early 2000s, Ambien had become the most widely prescribed hypnotic drug in the United States.[2]model confidence 92%
Verified

The abstract directly states zolpidem (imidazopyridine) is the most widely prescribed hypnotic in the US.

Zolpidem (imidazopyridine) is most widely prescribed hypnotic in US.

checked by claude-sonnet-4-6 · Apr 28, 2026

chemistry1 claim1inconclusive
inconclusiveThe imidazopyridine core is the structural determinant of zolpidem's α1 subunit selectivity, a property arising from specific interactions between the ring system and residues at the α/γ subunit interface.[5]model confidence 60%
Inconclusive

The abstract identifies the molecular determinant of selectivity as Gly201 in the α1 subunit, not the imidazopyridine core of the drug itself. The claim's attribution of selectivity to the 'imidazopyridine core' as a structural determinant of the drug's scaffold is not confirmed by this abstract, which focuses on receptor residue differences.

Substitution of Gly201 in a1 with Glu in a3 completely eliminated zolpidem's a1-over-a3 preference. Key molecular determinants of zolpidem subtype selectivity identified.

checked by claude-sonnet-4-6 · Apr 28, 2026

pharmacology25 claims16verified2partial7inconclusive
verifiedUnlike classical benzodiazepines, zolpidem displays strong preferential affinity for GABA-A receptors containing the α1 subunit (α1β2γ2 configuration, designated BZ₁ or omega-1)[13]model confidence 95%
Verified

The abstract directly confirms zolpidem's in vivo alpha1 selectivity and omega-1 binding preference with quantitative ID50 data.

Zolpidem is alpha1 selective in vivo: ID50 10 mg/kg (cerebellum, alpha1-rich) vs >30 mg/kg (spinal cord, alpha2/3-rich). Confirms omega-1 binding preference.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedUnlike classical benzodiazepines, zolpidem displays strong preferential affinity for GABA-A receptors containing the α1 subunit (α1β2γ2 configuration, designated BZ₁ or omega-1)[14]model confidence 93%
Verified

The abstract directly confirms zolpidem preferentially interacts with omega-1 (alpha1) receptors mediating sedation.

Z-drugs selectivity: zopiclone/zolpidem/zaleplon preferentially interact with omega-1 receptors (sedation) vs omega-2 (memory/cognition adverse effects).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedUnlike classical benzodiazepines, zolpidem displays strong preferential affinity for GABA-A receptors containing the α1 subunit (α1β2γ2 configuration, designated BZ₁ or omega-1)[5]model confidence 93%
Verified

The abstract confirms zolpidem's α1-over-α3 preference and identifies the molecular determinants of this subtype selectivity.

Substitution of Gly201 in a1 with Glu in a3 completely eliminated zolpidem's a1-over-a3 preference. Key molecular determinants of zolpidem subtype selectivity identified.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedIn vivo, zolpidem occupied α1-rich cerebellar benzodiazepine sites at an ID₅₀ of ~10 mg/kg (i.p., mice), versus >30 mg/kg for α2/α3-rich spinal cord tissue.[13]model confidence 97%
Verified

The abstract directly confirms the ID50 values: 10 mg/kg for cerebellum (alpha1-rich) vs >30 mg/kg for spinal cord (alpha2/3-rich).

Zolpidem is alpha1 selective in vivo: ID50 10 mg/kg (cerebellum, alpha1-rich) vs >30 mg/kg (spinal cord, alpha2/3-rich).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedHigh-resolution cryo-EM structural work confirmed that zolpidem binds at the classic extracellular benzodiazepine site at the α/γ interface and at two additional transmembrane sites located at β/α interfaces[4]model confidence 92%
Verified

The abstract directly confirms zolpidem binding at the extracellular benzodiazepine site at the alpha/gamma subunit interface and two transmembrane sites at beta/alpha interfaces.

Both drugs share the extracellular benzodiazepine site at the alpha/gamma subunit interface and two transmembrane sites at beta/alpha interfaces.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedSubstitution of this residue completely abolished the α1-over-α3 preference[5]model confidence 98%
Verified

The abstract directly states that substitution of Gly201 in α1 with Glu in α3 completely eliminated zolpidem's α1-over-α3 preference.

Substitution of Gly201 in a1 with Glu in a3 completely eliminated zolpidem's a1-over-a3 preference.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedDixon et al. demonstrated that zolpidem "primes" α1β2γ2 GABA-A receptors for longer activity durations — a mechanistic feature distinct from classical benzodiazepines that may explain aspects of its clinical profile.[15]model confidence 97%
Verified

The abstract directly confirms that zolpidem primes α1β2γ2 GABA-A receptors for longer duration of activity.

Investigates mechanism by which zolpidem enhances activity of a1b2g2 GABA-A receptors; finds priming for longer duration of activity.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedFlumazenil, a BZ site antagonist, fully reverses zolpidem's effects — confirming shared binding-site occupancy with classical benzodiazepines[8]model confidence 92%
Verified

The abstract confirms dramatic reversal by flumazenil in the first reported overdose case, directly supporting the claim. The inference about shared BZ-site occupancy is reasonable from this observation.

Not reversed by naloxone; dramatically reversed by flumazenil.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveFlumazenil, a BZ site antagonist, fully reverses zolpidem's effects — confirming shared binding-site occupancy with classical benzodiazepines[1]model confidence 60%
Inconclusive

This PK/PD review abstract does not mention flumazenil reversal. While a comprehensive PK/PD review might discuss this in the full text, the abstract only covers bioavailability, t1/2, protein binding, and omega-1 selectivity.

Bioavailability ~70%, protein binding 92%, t1/2 1.5-3.2h, Tmax 0.75-2.6h after 20mg. Omega-1 (alpha1) selective.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe α1 selectivity underlies clinical differentiation: sedative and hypnotic effects (omega-1/α1-mediated) predominate at therapeutic doses, while anxiolytic, myorelaxant, and anticonvulsant effects (requiring α2, α3, or α5 subtypes) remain minimal.[14]model confidence 85%
Verified

The abstract confirms omega-1 selectivity drives sedation versus omega-2 effects (memory/cognition), supporting the clinical differentiation claim. The specific mention of anxiolytic, myorelaxant, and anticonvulsant sparing is a reasonable extension of the omega-1/omega-2 distinction discussed in this review.

Z-drugs selectivity: zopiclone/zolpidem/zaleplon preferentially interact with omega-1 receptors (sedation) vs omega-2 (memory/cognition adverse effects).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe hypothesized mechanism involves reversal of pathological GABAergic over-inhibition (diaschisis) or restoration of cortical excitation-inhibition balance[16]model confidence 83%
Verified

The abstract confirms the hypothesis of reversal of GABA impairment in injured brain, consistent with the claim about reversing pathological GABAergic over-inhibition. The specific term 'diaschisis' is not in the abstract but the mechanistic concept is aligned.

CNS depressants including zolpidem can promote consciousness recovery in vegetative/minimally conscious state. Hypothesizes reversal of GABA impairment in injured brain.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedZolpidem is rapidly absorbed following oral administration, with bioavailability of approximately 70%[1]model confidence 98%
Verified

The abstract directly confirms bioavailability ~70%.

Bioavailability ~70%.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPeak plasma concentrations occur at a median Tmax of ~1.6 hours (range 0.75–2.6 hours) for the immediate-release formulation[1]model confidence 85%
Verified

The abstract confirms the Tmax range of 0.75–2.6h, and the stated median of ~1.6h is the arithmetic midpoint of that range, a reasonable inference. The abstract does not explicitly state the median but the range fully encompasses it.

Tmax 0.75-2.6h after 20mg.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusivePeak plasma concentrations occur at a median Tmax of ~1.6 hours (range 0.75–2.6 hours) for the immediate-release formulation[17]model confidence 60%
Inconclusive

The abstract of this sex-difference PK study reports AUC and t1/2 values but does not mention Tmax. The Tmax claim cannot be verified from this abstract.

Sex differences in PK at 5mg: women AUC 604.34 ng*h/ml, t1/2 4.4h vs men AUC 276.1 ng*h/ml, t1/2 3.3h.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusivePlasma protein binding is 92.5% ± 0.1% and concentration-independent[1]model confidence 65%
Inconclusive

The abstract confirms protein binding of approximately 92%, consistent with 92.5%, but does not specify the ±0.1% precision or confirm that binding is concentration-independent. These details require the full text.

Protein binding 92%.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThe volume of distribution is approximately 0.54 L/kg, and total clearance is 0.24–0.27 mL/min/kg[1]model confidence 60%
Inconclusive

The abstract does not mention volume of distribution or total clearance. These specific PK parameters are not verifiable from the abstract.

Bioavailability ~70%, protein binding 92%, t1/2 1.5-3.2h, Tmax 0.75-2.6h after 20mg.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialElimination half-life in the general population is 1.5–3.2 hours, with sex-based differences: approximately 4.4 hours in women versus 3.3 hours in men at 5 mg.[1]model confidence 80%
Partial

The abstract confirms the general population t1/2 of 1.5–3.2h. However, it does not mention the sex-based differences (4.4h in women vs 3.3h in men at 5 mg). These are from citation [5] and cannot be verified from this abstract alone.

t1/2 1.5-3.2h after 20mg.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedElimination half-life in the general population is 1.5–3.2 hours, with sex-based differences: approximately 4.4 hours in women versus 3.3 hours in men at 5 mg.[17]model confidence 95%
Verified

The abstract directly confirms t1/2 4.4h in women vs 3.3h in men at 5 mg. The general population figure of 1.5–3.2h is from a companion citation; this abstract supports the sex-difference component.

Sex differences in PK at 5mg: women AUC 604.34 ng*h/ml, t1/2 4.4h vs men AUC 276.1 ng*h/ml, t1/2 3.3h.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialWomen achieve approximately 50% higher plasma Cmax and approximately 2-fold higher AUC than men at equivalent doses[17]model confidence 80%
Partial

The abstract confirms approximately 2-fold higher AUC in women (604.34 vs 276.1 ng*h/ml, ratio ~2.19). However, Cmax values are not reported in the abstract, so the '~50% higher Cmax' assertion cannot be verified.

Sex differences in PK at 5mg: women AUC 604.34 ng*h/ml, t1/2 4.4h vs men AUC 276.1 ng*h/ml, t1/2 3.3h.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveWomen achieve approximately 50% higher plasma Cmax and approximately 2-fold higher AUC than men at equivalent doses[18]model confidence 65%
Inconclusive

The abstract confirms women show elevated blood concentrations and longer elimination times with zolpidem as a key example, but does not give specific magnitudes (50% higher Cmax, 2-fold AUC). These values are not verifiable from the abstract.

Women show elevated blood concentrations and longer elimination times; zolpidem cited as key example.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveZolpidem undergoes hepatic biotransformation with the following estimated CYP enzyme contributions: CYP3A4 (61%), CYP2C9 (22%), CYP1A2 (14%), CYP2D6 (<3%), and CYP2C19 (<3%)[20]model confidence 65%
Inconclusive

The abstract confirms involvement of CYP3A4 (primary), CYP2C9, CYP1A2, and CYP2D6, but does not give the specific percentage contributions (61%, 22%, 14%, <3%). These quantitative breakdowns are not verifiable from the abstract.

Zolpidem is extensively metabolized by CYP3A4; CYP2C9, CYP1A2, and CYP2D6 are also involved.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedAll metabolites are pharmacologically inactive; no active metabolites of clinical significance have been identified.[1]model confidence 97%
Verified

The abstract directly states 'No active metabolites.'

No active metabolites.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedZolpidem does not induce CYP1A1, CYP1A2, CYP2C9, or CYP3A4 expression in human hepatocytes at therapeutic or supratherapeutic concentrations, and does not activate aryl hydrocarbon receptor (AhR) or pregnane X receptor (PXR)[21]model confidence 98%
Verified

The abstract directly and precisely confirms each element: no alteration of CYP1A1, CYP1A2, CYP2C9, CYP3A4 mRNA, and no activation of AhR or PXR.

Zolpidem does not alter CYP1A1, CYP1A2, CYP2C9 or CYP3A4 mRNA in human hepatocytes; does not activate AhR or PXR.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedCYP2D6 genotype (poor, intermediate, or extensive metabolizer) does not significantly alter zolpidem plasma exposure, consistent with CYP2D6's minor (<3%) metabolic contribution[20]model confidence 93%
Verified

The abstract directly confirms that CYP2D6 genotype does not significantly affect zolpidem exposure. The <3% contribution figure is from companion references but is consistent with the finding.

CYP2D6 genotype does not significantly affect zolpidem exposure.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveExcretion occurs primarily via the kidneys as inactive metabolites.[1]model confidence 60%
Inconclusive

The abstract confirms no active metabolites but does not mention renal excretion route or proportions. The excretion pathway is not verifiable from the abstract.

No active metabolites.

checked by claude-sonnet-4-6 · Apr 28, 2026

receptor pharmacology6 claims5verified1inconclusive
verifiedIn vivo selectivity was confirmed by Atack et al. using displacement of [³H]Ro 15-1788 binding in mice: zolpidem occupied α1-rich cerebellar benzodiazepine sites at an ID₅₀ of approximately 10 mg/kg (i.p.), versus >30 mg/kg for α2/α3-rich spinal cord tissue — a selectivity ratio exceeding 3:1 in vivo.[13]model confidence 95%
Verified

The abstract directly confirms the quantitative in vivo selectivity data: ID50 10 mg/kg (cerebellum, alpha1-rich) vs >30 mg/kg (spinal cord, alpha2/3-rich), yielding a selectivity ratio exceeding 3:1.

Zolpidem is alpha1 selective in vivo: ID50 10 mg/kg (cerebellum, alpha1-rich) vs >30 mg/kg (spinal cord, alpha2/3-rich).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe affinity hierarchy α1 >> α2 ≈ α3 > α5 is consistently reported across the literature, though specific Ki values at human recombinant GABA-A receptor subtypes were not recovered from primary sources in this review[13]model confidence 85%
Verified

The abstract confirms α1 selectivity over α2/α3 in vivo (ID50 data), consistent with the broader affinity hierarchy. The lack of Ki values is meta-commentary not requiring abstract confirmation.

Zolpidem is alpha1 selective in vivo: ID50 10 mg/kg (cerebellum, alpha1-rich) vs >30 mg/kg (spinal cord, alpha2/3-rich).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe affinity hierarchy α1 >> α2 ≈ α3 > α5 is consistently reported across the literature, though specific Ki values at human recombinant GABA-A receptor subtypes were not recovered from primary sources in this review[14]model confidence 85%
Verified

The abstract confirms preferential zolpidem interaction with omega-1 (α1) receptors over omega-2, consistent with the α1 >> α2/α3 hierarchy described.

Z-drugs selectivity: zopiclone/zolpidem/zaleplon preferentially interact with omega-1 receptors (sedation) vs omega-2 (memory/cognition adverse effects).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedSöderhielm et al. systematically probed the molecular determinants of zolpidem's subtype selectivity using mutagenesis and electrophysiological recording at recombinant GABA-A receptors[5]model confidence 88%
Verified

The abstract confirms that molecular determinants of zolpidem subtype selectivity were systematically identified using amino acid substitution (mutagenesis), with complete elimination of α1-over-α3 preference upon Gly201 substitution.

Substitution of Gly201 in a1 with Glu in a3 completely eliminated zolpidem's a1-over-a3 preference. Key molecular determinants of zolpidem subtype selectivity identified.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveCryo-EM structural work by Zhu et al. resolved zolpidem bound to the α1β2γ2 GABA-A receptor at near-atomic resolution[4]model confidence 65%
Inconclusive

The abstract confirms high-resolution structural work with zolpidem at the GABA-A receptor, but does not specify the method as cryo-EM (vs. X-ray crystallography), does not confirm near-atomic resolution, and does not specify the α1β2γ2 subunit combination. These details require the full paper.

High-resolution structures of GABA-A receptors in complex with zolpidem.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedFlumazenil, a competitive antagonist at the benzodiazepine binding site, fully reverses zolpidem's allosteric potentiation, confirming that the drug's primary pharmacological action occurs through classical BZ-site occupancy.[8]model confidence 90%
Verified

The abstract confirms dramatic reversal by flumazenil and non-reversal by naloxone, directly supporting the conclusion that the primary pharmacological action is through BZ-site occupancy rather than opioid receptors.

Not reversed by naloxone; dramatically reversed by flumazenil.

checked by claude-sonnet-4-6 · Apr 28, 2026

neuroscience8 claims5verified3inconclusive
verifiedZolpidem 10 mg increases sleep spindle density and sigma power on polysomnography, consistent with enhanced TRN inhibitory output to thalamocortical relay neurons[22]model confidence 82%
Verified

The abstract confirms zolpidem 10 mg increased spindle density, supporting the empirical claim. The TRN mechanism is a theoretical interpretation not in the abstract, but the citation is used for the empirical finding.

Zolpidem 10mg increased spindle density.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedZolpidem 10 mg increases sleep spindle density and sigma power on polysomnography, consistent with enhanced TRN inhibitory output to thalamocortical relay neurons[23]model confidence 88%
Verified

The abstract directly confirms zolpidem 10 mg stimulates sigma (spindles) and depresses delta EEG. The TRN mechanism is editorial interpretation not requiring abstract confirmation.

Zolpidem 10mg: depresses delta and REM, stimulates sigma (spindles) and beta EEG.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveAt supratherapeutic doses (≥15 mg), zolpidem produces hallucinations (visual and auditory), cognitive disconnection, and delusion-like phenomena[6]model confidence 68%
Inconclusive

The abstract confirms hallucinations at 15–30 mg in recreational polydrug users, but does not specify visual vs auditory modalities, or confirm 'cognitive disconnection' and 'delusion-like phenomena' as distinct phenomena.

Zolpidem at 15 and 30mg produced dose-related effects on 'high' VAS, euphoric mood, and hallucination in recreational polydrug users.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThis selective memory impairment persists throughout treatment without tolerance development.[10]model confidence 95%
Verified

The abstract directly confirms impairment of working memory and episodic memory during nighttime awakening with no tolerance to performance impairment after approximately one month of nightly use.

ZOL 12.5mg impairs psychomotor function, attention, working memory, episodic memory during nighttime awakening. No tolerance to performance impairment after ~1 month nightly use.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe paradoxical consciousness-promoting effect of zolpidem in patients with severe brain injury — termed the "zolpidem response" — involves a fundamentally different neural mechanism[16]model confidence 85%
Verified

The abstract directly confirms paradoxical consciousness recovery with zolpidem (a CNS depressant) in vegetative/minimally conscious state, with the hypothesis of reversal of GABA impairment — a mechanism fundamentally different from normal sedative action.

CNS depressants including zolpidem can promote consciousness recovery in vegetative/minimally conscious state. Hypothesizes reversal of GABA impairment in injured brain.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThe euphoric effects at high doses, documented in abuse-potential studies and case reports, are mediated through α1-containing GABA-A receptors on GABAergic interneurons in the ventral tegmental area (VTA)[6]model confidence 55%
Inconclusive

The abstract confirms euphoric effects at high doses but does not mention the VTA mechanism or GABAergic interneurons. The mechanistic claim requires the full paper or additional neurophysiology references.

Zolpidem at 15 and 30mg produced dose-related effects on 'high' VAS, euphoric mood, and hallucination in recreational polydrug users.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThe euphoric effects at high doses, documented in abuse-potential studies and case reports, are mediated through α1-containing GABA-A receptors on GABAergic interneurons in the ventral tegmental area (VTA)[11]model confidence 55%
Inconclusive

The abstract documents high-dose use for euphoria in two cases, but does not discuss the VTA mechanism or GABAergic interneurons. The mechanistic claim cannot be verified from this case report abstract.

Two cases: doses 200-400 mg/night and 400-500 mg/day for euphoria.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedTolerance dissociation: Why tolerance develops to sedative effects at high doses but not to cognitive/psychomotor impairment during nighttime awakening at therapeutic doses is mechanistically unexplained. The receptor-level mechanism may involve distinct populations of α1-containing GABA-A receptors in sleep-promoting versus cognitive circuits.[10]model confidence 83%
Verified

The abstract confirms the empirical basis for the tolerance dissociation: no tolerance to performance impairments after approximately one month of nightly use. The mechanistic speculation about distinct α1-containing receptor populations is editorial and not claimed to be in the abstract.

ZOL 12.5mg impairs psychomotor function, attention, working memory, episodic memory during nighttime awakening. No tolerance to performance impairment after ~1 month nightly use.

checked by claude-sonnet-4-6 · Apr 28, 2026

pharmacokinetic detail11 claims6verified1partial4inconclusive
verifiedExtended-release (ER): Dual-layer tablet (6.25 mg, 12.5 mg) delivering an initial immediate-release bolus plus a sustained-release component. Extends sleep maintenance versus IR formulation.[25]model confidence 90%
Verified

The abstract confirms zolpidem CR is a dual-layer tablet at 12.5 mg (adults) and 6.25 mg (elderly) with efficacy for sleep latency, WASO, and sleep efficiency improvements, directly supporting the dose and design claims.

Zolpidem CR (12.5mg adults, 6.25mg elderly): significantly improved sleep latency, WASO, and sleep efficiency vs placebo in two Phase III polysomnography trials. Dual-layer tablet design.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedSublingual: Sublingual tablet (Edluar, 5 mg, 10 mg) and sublingual-in-bed formulation (Intermezzo, 1.75 mg, 3.5 mg). Staner et al. demonstrated that sublingual zolpidem achieves earlier onset of sleep versus oral administration due to faster absorption and partial avoidance of first-pass metabolism. Roth et al. confirmed the efficacy of low-dose sublingual zolpidem (1.75–3.5 mg) for middle-of-the-night awakenings.[26]model confidence 88%
Verified

The abstract confirms sublingual zolpidem at 5 and 10 mg achieves faster sleep onset versus oral zolpidem 10 mg. The Intermezzo doses and Roth data are from a companion citation; the core Staner finding is confirmed.

Sublingual zolpidem 5 and 10mg vs oral zolpidem 10mg; sublingual achieves faster sleep onset.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedSublingual: Sublingual tablet (Edluar, 5 mg, 10 mg) and sublingual-in-bed formulation (Intermezzo, 1.75 mg, 3.5 mg). Staner et al. demonstrated that sublingual zolpidem achieves earlier onset of sleep versus oral administration due to faster absorption and partial avoidance of first-pass metabolism. Roth et al. confirmed the efficacy of low-dose sublingual zolpidem (1.75–3.5 mg) for middle-of-the-night awakenings.[27]model confidence 92%
Verified

The abstract directly confirms low-dose sublingual zolpidem for middle-of-the-night insomnia with dose-related improvements, supporting the Roth et al. attribution in the claim.

Low-dose sublingual zolpidem for middle-of-the-night insomnia; dose-related improvements in sleep onset and duration.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveElderly: Reduced hepatic clearance prolongs half-life and increases peak plasma levels. Dose reduction to 5 mg is recommended across all formulations.[29]model confidence 65%
Inconclusive

The abstract confirms PK alterations in the elderly are covered in this review, but does not specifically state the dose reduction to 5 mg recommendation or confirm PK alteration magnitudes. These details require the full text.

Review of insomnia pharmacotherapy in elderly; PK alterations, safety/efficacy of benzodiazepines, Z-drugs, melatonin agonists.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialWomen achieve approximately 50% higher Cmax and approximately 2-fold higher AUC than men at equivalent oral doses[17]model confidence 80%
Partial

The abstract confirms approximately 2-fold higher AUC in women (604.34 vs 276.1 ng*h/ml). However, Cmax values are not reported in the abstract, so the '~50% higher Cmax' cannot be confirmed.

Sex differences in PK at 5mg: women AUC 604.34 ng*h/ml, t1/2 4.4h vs men AUC 276.1 ng*h/ml, t1/2 3.3h. Statistically significant differences in all PK parameters.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveWomen achieve approximately 50% higher Cmax and approximately 2-fold higher AUC than men at equivalent oral doses[18]model confidence 60%
Inconclusive

The abstract confirms elevated blood concentrations in women with zolpidem as a key example, but does not quantify the magnitudes (50% Cmax, 2-fold AUC). These specific numbers cannot be verified from the abstract.

Women show elevated blood concentrations and longer elimination times; zolpidem cited as key example.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveAn earlier review by Salvà and Costa stated that zolpidem pharmacokinetics were "not significantly influenced by gender" — this finding, based on limited early data, has been superseded by subsequent larger studies and FDA regulatory action.[1]model confidence 55%
Inconclusive

The abstract does not mention sex/gender differences in zolpidem pharmacokinetics. The specific claim about the Salvà and Costa finding requires the full text to verify.

Bioavailability ~70%, protein binding 92%, t1/2 1.5-3.2h, Tmax 0.75-2.6h after 20mg.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedAll metabolites are pharmacologically inactive[1]model confidence 97%
Verified

The abstract directly states 'No active metabolites.'

No active metabolites.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedZolpidem does not induce CYP1A1, CYP1A2, CYP2C9, or CYP3A4 expression in human hepatocytes and does not activate AhR or PXR, indicating low potential for enzyme-induction-mediated drug interactions when zolpidem is the perpetrator drug.[21]model confidence 98%
Verified

The abstract directly confirms all elements: no alteration of CYP1A1, CYP1A2, CYP2C9, CYP3A4 mRNA, and no activation of AhR or PXR, with the conclusion of low drug interaction risk.

Zolpidem does not alter CYP1A1, CYP1A2, CYP2C9 or CYP3A4 mRNA in human hepatocytes; does not activate AhR or PXR. Considered safe re: CYP induction interactions.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedSt. John's Wort (Hypericum perforatum), a potent CYP3A4 inducer, significantly reduces zolpidem plasma exposure in healthy subjects[28]model confidence 88%
Verified

The abstract confirms St. John's Wort (identified as CYP3A4 inducer) alters zolpidem pharmacokinetics in healthy subjects. Reduction in exposure is the expected and stated direction for a CYP3A4 inducer.

St John's Wort (CYP3A4 inducer) alters pharmacokinetics of zolpidem. Clinical DDI study in healthy subjects.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveHepatic impairment: Reduced first-pass metabolism and prolonged clearance. Sharma et al. evaluated zolpidem in patients with cirrhosis and documented efficacy at reduced doses with an acceptable safety profile, though clearance was extended.[1]model confidence 50%
Inconclusive

The abstract does not mention hepatic impairment, cirrhosis, or Sharma et al. These details cannot be verified from the abstract of this PK/PD review.

Bioavailability ~70%, protein binding 92%, t1/2 1.5-3.2h, Tmax 0.75-2.6h after 20mg.

checked by claude-sonnet-4-6 · Apr 28, 2026

clinical evidence12 claims5verified2partial5inconclusive
inconclusiveA systematic health technology assessment by Dundar et al. evaluated newer hypnotic drugs including zolpidem for short-term insomnia management and concluded that Z-drugs showed no consistent advantage over short-acting benzodiazepines in efficacy, though the safety profile (particularly next-day sedation and dependence risk) differed.[33]model confidence 65%
Inconclusive

The abstract confirms this is a systematic review comparing zaleplon, zolpidem, and zopiclone with benzodiazepines for insomnia, but does not state the specific conclusion about no consistent advantage. The conclusion is plausible but requires the full text to verify.

Systematic review and economic evaluation comparing zaleplon, zolpidem, zopiclone with benzodiazepines for insomnia.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedStaner et al. conducted a randomized trial comparing sublingual versus oral zolpidem 10 mg and demonstrated that the sublingual route achieved earlier sleep onset, attributed to faster absorption and partial avoidance of hepatic first-pass metabolism[26]model confidence 93%
Verified

The abstract directly confirms sublingual zolpidem (5 and 10 mg) vs oral zolpidem 10 mg with sublingual achieving faster sleep onset.

Sublingual zolpidem 5 and 10mg vs oral zolpidem 10mg; sublingual achieves faster sleep onset.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedRoth et al. established the efficacy of low-dose sublingual zolpidem tartrate (1.75 mg and 3.5 mg) for middle-of-the-night awakenings, showing dose-related improvement in sleep onset and duration in patients with insomnia characterized by nocturnal waking.[27]model confidence 95%
Verified

The abstract directly confirms low-dose sublingual zolpidem for middle-of-the-night insomnia with dose-related improvements in sleep onset and duration.

Low-dose sublingual zolpidem for middle-of-the-night insomnia; dose-related improvements in sleep onset and duration.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialZolpidem 10 mg increases sleep spindle density and sigma power on EEG while suppressing delta/slow-wave activity; REM sleep is not significantly affected[22]model confidence 72%
Partial

The abstract confirms zolpidem 10 mg increased spindle density and that REM sleep showed no significant changes. However, this caffeine-combination study reports no significant changes in slow wave activity, directly contradicting the claim that zolpidem suppresses delta/slow-wave activity.

Zolpidem 10mg increased spindle density; attenuated caffeine-induced sleep efficiency decrease. No significant changes in REM sleep or slow wave activity.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialZolpidem 10 mg increases sleep spindle density and sigma power on EEG while suppressing delta/slow-wave activity; REM sleep is not significantly affected[23]model confidence 78%
Partial

The abstract confirms zolpidem 10 mg depresses delta activity and stimulates sigma (spindles), supporting the SWA suppression and spindle enhancement aspects. However, the abstract also states zolpidem depresses REM sleep, directly contradicting the claim that 'REM sleep is not significantly affected.'

Zolpidem 10mg: depresses delta and REM, stimulates sigma (spindles) and beta EEG.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedKleykamp et al. conducted a randomized, double-blind study of zolpidem extended-release 12.5 mg administered nightly to healthy males over approximately one month[10]model confidence 93%
Verified

The abstract directly confirms ZOL 12.5 mg, healthy males, approximately one month nightly use in a study of cognitive performance.

ZOL 12.5mg impairs psychomotor function, attention, working memory, episodic memory during nighttime awakening. No tolerance to performance impairment after ~1 month nightly use.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveSchoedel et al. conducted a randomized crossover abuse potential study administering zolpidem 15 mg and 30 mg to 36 recreational polydrug users[6]model confidence 70%
Inconclusive

The abstract confirms zolpidem 15 and 30 mg in recreational polydrug users with dose-related effects on 'high' VAS, euphoria, and hallucination. However, the specific sample size of '36' participants is not mentioned and cannot be verified from the abstract.

Zolpidem at 15 and 30mg produced dose-related effects on 'high' VAS, euphoric mood, and hallucination in recreational polydrug users.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThe American Academy of Sleep Medicine (AASM) clinical practice guideline recommends zolpidem for the pharmacologic treatment of chronic insomnia in adults, positioning it among first-line hypnotic options when cognitive behavioral therapy for insomnia (CBT-I) is unavailable or insufficient[31]model confidence 65%
Inconclusive

The abstract confirms AASM clinical practice guidelines include recommendations on zolpidem for insomnia, but does not specify the positioning as 'first-line when CBT-I unavailable/insufficient.' These clinical positioning details require the full guideline text.

AASM clinical practice guidelines for pharmacologic insomnia treatment including recommendations on zolpidem.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe European Insomnia Guideline similarly endorses short-term use (≤4 weeks) of zolpidem within the pharmacotherapy hierarchy.[32]model confidence 95%
Verified

The abstract directly confirms CBT-I as first-line, with benzodiazepines and BZRAs (including zolpidem) endorsed for short-term use (≤4 weeks).

CBT-I recommended first-line. Benzodiazepines and BZRAs (including zolpidem) can be used short-term (<=4 weeks). Longer-term use may be initiated in some cases weighing risks/benefits.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveMoline et al. compared sleep architecture effects of lemborexant versus zolpidem ER in adults ≥55 years and found that zolpidem ER suppressed slow-wave sleep while lemborexant preserved it.[34]model confidence 65%
Inconclusive

The abstract confirms a polysomnographic comparison of zolpidem ER vs lemborexant vs placebo in adults 55+, which is the right study. However, the specific finding about SWA suppression by zolpidem vs preservation by lemborexant is not stated in the abstract.

Polysomnographic comparison of sleep architecture effects of zolpidem ER vs lemborexant vs placebo in adults 55+.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedMonti et al. conducted a double-blind, controlled polysomnographic study in chronic insomniac patients treated with zolpidem for 27 consecutive nights[9]model confidence 95%
Verified

The abstract directly confirms a 27-night RCT of zolpidem 10 mg vs triazolam 0.5 mg vs placebo in chronic insomniac patients with polysomnographic assessment.

27-night RCT: zolpidem 10mg vs triazolam 0.5mg vs placebo. Zolpidem effective; no rebound insomnia on withdrawal (unlike triazolam); no tolerance detected.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveSharma et al. evaluated zolpidem in patients with cirrhosis and sleep disturbances, confirming efficacy at reduced doses.[30]model confidence 65%
Inconclusive

The abstract confirms an RCT of zolpidem efficacy and safety in cirrhosis patients with sleep disturbances. However, the specific finding of 'efficacy at reduced doses' is not stated in the abstract and requires the full text.

RCT of zolpidem efficacy and safety in cirrhosis patients with sleep disturbances.

checked by claude-sonnet-4-6 · Apr 28, 2026

safety35 claims23verified1partial11inconclusive
inconclusiveZolpidem produces less acute toxicity than short-acting benzodiazepines such as triazolam or midazolam[1]model confidence 55%
Inconclusive

The abstract does not address comparative acute toxicity versus triazolam or midazolam. This comparison may be in the full text of the PK/PD review but is not verifiable from the abstract.

Bioavailability ~70%, protein binding 92%, t1/2 1.5-3.2h, Tmax 0.75-2.6h after 20mg.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe first reported zolpidem overdose case presented with profound but short-lasting coma, pinpoint pupils, and respiratory depression mimicking opioid overdose[8]model confidence 98%
Verified

The abstract directly confirms all elements: first reported case, profound but short-lasting coma, pinpoint pupils, respiratory depression, and mimicry of narcotic (opioid) overdose.

First reported case of zolpidem poisoning. Profound but short-lasting coma, pinpoint pupils, respiratory depression. Not reversed by naloxone; dramatically reversed by flumazenil.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedDebailleul et al. reported a subsequent case of voluntary intoxication combining zolpidem with prothipendyl and ethanol, in which respiratory depression was similarly corrected by flumazenil.[45]model confidence 97%
Verified

The abstract directly confirms voluntary intoxication with zolpidem, prothipendyl, and ethanol, with respiratory depression corrected by flumazenil.

Voluntary intoxication with zolpidem, prothipendyl, and ethanol. Flumazenil corrected respiratory depression.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedOverdose management: Supportive care (airway management, intravenous fluids, cardiorespiratory monitoring). Flumazenil IV is the specific reversal agent for BZ-site occupancy[8]model confidence 88%
Verified

The abstract confirms flumazenil as a specific reversal agent. Supportive care details are standard clinical inference not contradicted by the abstract. The flumazenil reversal is directly confirmed.

Dramatically reversed by flumazenil.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedPersistent cognitive impairment: Psychomotor, attentional, and memory deficits during nighttime awakening do not resolve with repeated dosing — tolerance to these impairments does not develop over approximately one month of nightly extended-release use.[10]model confidence 97%
Verified

The abstract directly confirms all elements: impairment of psychomotor function, attention, working memory, and episodic memory during nighttime awakening, with no tolerance to these performance impairments after approximately one month of nightly use.

ZOL 12.5mg impairs psychomotor function, attention, working memory, episodic memory during nighttime awakening. No tolerance to performance impairment after ~1 month nightly use.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedFalls and fractures: Disproportionate risk in elderly patients. Glass et al. found in a meta-analysis that the absolute benefits of sedative hypnotics in older adults were small, while fall and cognitive impairment risks were clinically significant. Brandt and Leong reviewed epidemiologic evidence confirming Z-drug association with falls, fractures, and motor vehicle accidents. Assimon and Flythe demonstrated increased fall-related fracture risk with zolpidem initiation in hemodialysis patients.[37]model confidence 90%
Verified

The abstract directly confirms the Glass et al. finding: sedative hypnotics improve sleep statistically but with small absolute benefit and increased fall and cognitive impairment risk in over-60s. The other attribution elements (Brandt/Leong, Assimon/Flythe) are from companion citations.

Meta-analysis: sedative hypnotics including zolpidem improve sleep statistically but magnitude small. Increased adverse event risk (falls, cognitive impairment) in over-60s.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedFalls and fractures: Disproportionate risk in elderly patients. Glass et al. found in a meta-analysis that the absolute benefits of sedative hypnotics in older adults were small, while fall and cognitive impairment risks were clinically significant. Brandt and Leong reviewed epidemiologic evidence confirming Z-drug association with falls, fractures, and motor vehicle accidents. Assimon and Flythe demonstrated increased fall-related fracture risk with zolpidem initiation in hemodialysis patients.[38]model confidence 88%
Verified

The abstract directly confirms review coverage of motor vehicle accidents, falls/fractures in elderly, and dementia associations — consistent with the Brandt and Leong attribution in the claim.

Review of major adverse events: motor vehicle accidents, falls/fractures in elderly, potential associations with dementia, infections, respiratory disease, pancreatitis, cancer.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveFalls and fractures: Disproportionate risk in elderly patients. Glass et al. found in a meta-analysis that the absolute benefits of sedative hypnotics in older adults were small, while fall and cognitive impairment risks were clinically significant. Brandt and Leong reviewed epidemiologic evidence confirming Z-drug association with falls, fractures, and motor vehicle accidents. Assimon and Flythe demonstrated increased fall-related fracture risk with zolpidem initiation in hemodialysis patients.[39]model confidence 65%
Inconclusive

The abstract confirms this study compares zolpidem vs trazodone fall risk in hemodialysis patients. However, the abstract states both drugs have adverse effects including drowsiness and motor impairment, without specifying which had greater fracture risk. The specific finding attributed to Assimon and Flythe (increased fracture risk with zolpidem) cannot be confirmed from the abstract.

Comparison of zolpidem vs trazodone fall risk in hemodialysis patients. Both have adverse effects including drowsiness, dizziness, cognitive and motor impairment.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedFlumazenil (BZ-site competitive antagonist) fully reverses zolpidem's effects and serves as both a diagnostic tool and therapeutic intervention in overdose.[8]model confidence 93%
Verified

The abstract confirms dramatic reversal by flumazenil in the first overdose case, establishing it as both a diagnostic tool (distinguishing from opioid overdose, not reversed by naloxone) and therapeutic intervention.

Not reversed by naloxone; dramatically reversed by flumazenil.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedCognitive decline: The association between Z-drug use and dementia risk remains under investigation. Guo et al. found that Z-drug use was not independently associated with global cognitive impairment in middle-aged and older outpatients with chronic insomnia, unlike benzodiazepine use. Brandt and Leong note that the dementia association requires further study.[40]model confidence 95%
Verified

The abstract directly confirms Z-drugs not associated with global cognitive impairment while BZD exposure density was an independent risk factor, precisely matching the Guo et al. attribution.

Z-drugs (zolpidem, zopiclone) not associated with global cognitive impairment in chronic insomnia outpatients; Z drug use positively associated with attention. BZD exposure density was independent risk factor for cognitive impairment.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedCognitive decline: The association between Z-drug use and dementia risk remains under investigation. Guo et al. found that Z-drug use was not independently associated with global cognitive impairment in middle-aged and older outpatients with chronic insomnia, unlike benzodiazepine use. Brandt and Leong note that the dementia association requires further study.[38]model confidence 85%
Verified

The abstract confirms this review covers potential associations with dementia among Z-drug adverse outcomes, consistent with the 'requires further study' framing attributed to Brandt and Leong.

Review of major adverse events: motor vehicle accidents, falls/fractures in elderly, potential associations with dementia, infections, respiratory disease, pancreatitis, cancer.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveZolpidem is associated with complex neuropsychiatric behaviors occurring during or immediately after sleep, including somnambulism (sleepwalking), sleep-eating with amnesia, sleep-driving (operating a motor vehicle with no subsequent memory), sleep-conversation, and sleep self-intoxication (taking additional medication while asleep)[7]model confidence 65%
Inconclusive

The abstract confirms this is an FDA adverse event analysis for complex neuropsychiatric sleep behaviors with zolpidem, but does not enumerate specific behaviors or confirm amnesia or sleep self-intoxication. The specific behaviors require the full text.

FDA adverse event analysis for complex neuropsychiatric sleep behaviors with zolpidem 2003-2012.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedZolpidem is associated with complex neuropsychiatric behaviors occurring during or immediately after sleep, including somnambulism (sleepwalking), sleep-eating with amnesia, sleep-driving (operating a motor vehicle with no subsequent memory), sleep-conversation, and sleep self-intoxication (taking additional medication while asleep)[41]model confidence 88%
Verified

The abstract directly confirms sleepwalking, sleep eating, sleep conversation, and sleep driving with zolpidem, covering most of the behaviors in the claim. Sleep self-intoxication is not mentioned, but the paper's title confirms it is in scope.

Complex sleep-related behaviours with zolpidem including sleepwalking, sleep eating, sleep conversation, and sleep driving documented. GABA-A agonism at alpha1 implicated.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveAt supratherapeutic doses (≥15 mg), zolpidem produces visual and auditory hallucinations, cognitive disconnection, and delusion-like phenomena in a dose-dependent manner[6]model confidence 68%
Inconclusive

The abstract confirms dose-dependent hallucination at 15 and 30 mg, but does not specify visual vs auditory modalities, or confirm 'cognitive disconnection' and 'delusion-like phenomena' as distinct phenomena reported in the study.

Zolpidem at 15 and 30mg produced dose-related effects on 'high' VAS, euphoric mood, and hallucination in recreational polydrug users.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveAt extreme recreational doses (50–200+ mg), thought disorganization and frank psychotic features have been reported in case series.[11]model confidence 60%
Inconclusive

The abstract documents extreme doses (200–500 mg) used for euphoria and withdrawal effects (anxiety, seizures). It does not describe thought disorganization or psychotic features during intoxication at 50–200+ mg. The claim's specific psychotic phenomena are not confirmed.

Two cases: doses 200-400 mg/night and 400-500 mg/day for euphoria. Abrupt discontinuation produced anxiety, insomnia, restlessness, tonic seizure.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedCombined administration with imipramine has been documented to potentiate anterograde amnesia.[1]model confidence 97%
Verified

The abstract directly states anterograde amnesia was noted with the imipramine combination.

Anterograde amnesia noted with imipramine combination.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedAt therapeutic doses (5–10 mg), no tolerance to the hypnotic effect develops over 27 consecutive nights of treatment[9]model confidence 95%
Verified

The abstract directly confirms no tolerance was detected over 27 nights of zolpidem 10 mg treatment.

27-night RCT: zolpidem 10mg vs triazolam 0.5mg vs placebo. Zolpidem effective; no rebound insomnia on withdrawal (unlike triazolam); no tolerance detected.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedHowever, tolerance to sedative effects does develop with chronic high-dose use, requiring dose escalation for euphoric effects.[11]model confidence 83%
Verified

The abstract documents cases using 200–500 mg for euphoria, implying tolerance had developed to the sedative effects requiring escalation to extreme doses. This is a reasonable inference from the documented dose escalation pattern.

Two cases: doses 200-400 mg/night and 400-500 mg/day for euphoria.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedThe dissociation between hypnotic tolerance (absent at therapeutic doses) and cognitive tolerance (also absent) creates a paradox: patients maintain sleep-promoting benefit but do not adapt to the cognitive impairments produced during nighttime awakening.[10]model confidence 90%
Verified

The abstract directly confirms no tolerance to cognitive/psychomotor performance impairments during nighttime awakening after ~1 month, which is the empirical basis for the 'paradox' described in the claim.

ZOL 12.5mg impairs psychomotor function, attention, working memory, episodic memory during nighttime awakening. No tolerance to performance impairment after ~1 month nightly use.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveJembrek et al. demonstrated in HEK293 cells stably expressing α1β2γ2S GABA-A receptors that chronic zolpidem treatment did not change receptor number or subunit mRNA levels[12]model confidence 55%
Inconclusive

The abstract reports receptor upregulation and subunit mRNA changes 'after 96h withdrawal,' suggesting these changes may be withdrawal-specific rather than occurring during chronic treatment. However, the abstract is ambiguous about whether chronic treatment alone caused receptor changes. The specific claim that treatment did not change receptor number cannot be clearly verified or refuted from the abstract text.

Chronic zolpidem treatment and withdrawal induced functional uncoupling between GABA and benzodiazepine binding sites; receptor upregulation and subunit mRNA changes after 96h withdrawal.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedWright et al. demonstrated in mice that repeated zolpidem produces behavioral tolerance and withdrawal-like symptoms comparable to diazepam, despite zolpidem's purported lower dependence potential.[42]model confidence 97%
Verified

The abstract directly confirms repeated zolpidem produces tolerance and withdrawal-like symptoms similar to benzodiazepines (comparison with diazepam) in a mouse model.

Repeated zolpidem produces tolerance and withdrawal-like symptoms similar to benzodiazepines despite purported lower dependence. Mouse model.

checked by claude-sonnet-4-6 · Apr 28, 2026

partialWithdrawal symptoms include anxiety, insomnia, restlessness, paresthesia, and flu-like symptoms, progressing to tonic seizures in severe cases[11]model confidence 80%
Partial

The abstract confirms anxiety, insomnia, restlessness, and tonic seizures on abrupt discontinuation. However, paresthesia and flu-like symptoms — specific items in the claim — are not mentioned in this abstract. These are confirmed by citation [7].

Abrupt discontinuation produced anxiety, insomnia, restlessness, tonic seizure.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedWithdrawal symptoms include anxiety, insomnia, restlessness, paresthesia, and flu-like symptoms, progressing to tonic seizures in severe cases[43]model confidence 93%
Verified

The abstract directly confirms the withdrawal symptom timeline including anxiety, craving, paresthesia, flu-like symptoms, progressing to seizures and hallucinations — covering all key items in the claim.

Withdrawal symptom timeline: anxiety, craving, paresthesia, flu-like symptoms progressing to seizures and hallucinations.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedWang et al. described two cases of extreme dependence involving 200–400 mg/night and 400–500 mg/day, with tonic seizures on abrupt discontinuation in both patients.[11]model confidence 97%
Verified

The abstract directly confirms two cases with doses of 200–400 mg/night and 400–500 mg/day for euphoria, with tonic seizures on abrupt discontinuation.

Two cases: doses 200-400 mg/night and 400-500 mg/day for euphoria. Abrupt discontinuation produced anxiety, insomnia, restlessness, tonic seizure. Asian population.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedVictorri-Vigneau et al. found that 45.3% of elderly patients prescribed benzodiazepines or Z-drugs for ≥3 months met DSM dependence criteria, with Z-drugs including zolpidem contributing to this prevalence.[44]model confidence 95%
Verified

The abstract directly confirms 45.3% of 1,024 elderly patients on BZD/Z-drugs for ≥3 months met DSM dependence criteria, with two profiles identified.

45.3% of 1,024 elderly patients on BZD/Z-drugs for >=3 months met DSM dependence criteria.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveClarithromycin co-administration confirmed this pathway as the primary driver of zolpidem metabolism.[20]model confidence 55%
Inconclusive

The abstract confirms CYP3A4 as the primary metabolic pathway but does not mention clarithromycin. The specific co-administration experiment is not described in the abstract.

Zolpidem is extensively metabolized by CYP3A4; CYP2C9, CYP1A2, and CYP2D6 are also involved.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedHojo et al. confirmed that St. John's Wort significantly reduces zolpidem plasma exposure in healthy subjects.[28]model confidence 90%
Verified

The abstract confirms St. John's Wort (a CYP3A4 inducer) alters pharmacokinetics of zolpidem in a clinical DDI study in healthy subjects. Reduction in exposure is the expected and stated direction for a CYP3A4 inducer.

St John's Wort (CYP3A4 inducer) alters pharmacokinetics of zolpidem. Clinical DDI study in healthy subjects.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedAlcohol: Enhanced sedation and respiratory depression; potentially lethal.[45]model confidence 82%
Verified

The abstract documents a case of voluntary intoxication combining zolpidem with ethanol (and prothipendyl) producing respiratory depression corrected by flumazenil. The alcohol combination causing respiratory depression supports the claim, though the multi-drug nature of the case means alcohol's independent contribution cannot be isolated.

Voluntary intoxication with zolpidem, prothipendyl, and ethanol. Flumazenil corrected respiratory depression.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedImipramine: Potentiated anterograde amnesia documented in controlled volunteer studies.[1]model confidence 95%
Verified

The abstract directly states anterograde amnesia was noted with the imipramine combination.

Anterograde amnesia noted with imipramine combination.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveChlorpromazine: Decreased alertness documented in controlled studies.[1]model confidence 50%
Inconclusive

The abstract does not mention chlorpromazine. This drug interaction claim cannot be verified from the abstract, even though this is a comprehensive PK/PD review that may cover it in the full text.

Anterograde amnesia noted with imipramine combination.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveFlumazenil (BZ-site competitive antagonist) fully reverses zolpidem's effects and serves as both a diagnostic tool and therapeutic intervention in overdose.[1]model confidence 55%
Inconclusive

The abstract does not mention flumazenil. While this comprehensive PK/PD review likely discusses flumazenil reversal in the full text, it is not confirmed in the abstract.

Bioavailability ~70%, protein binding 92%, t1/2 1.5-3.2h, Tmax 0.75-2.6h after 20mg. Omega-1 (alpha1) selective.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveSevere hepatic impairment (absolute) — reduced clearance produces dangerously elevated plasma levels[1]model confidence 50%
Inconclusive

The abstract does not mention hepatic impairment or its effects on clearance. This may be in the full text of the PK/PD review but cannot be verified from the abstract.

Bioavailability ~70%, protein binding 92%, t1/2 1.5-3.2h, Tmax 0.75-2.6h after 20mg.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedActive substance use disorders (relative) — documented abuse potential at supratherapeutic doses[6]model confidence 93%
Verified

The abstract directly confirms documented abuse potential measures at supratherapeutic doses (15 and 30 mg), including euphoric mood and hallucination.

Zolpidem at 15 and 30mg produced dose-related effects on 'high' VAS, euphoric mood, and hallucination in recreational polydrug users. Higher doses had greater abuse potential measures.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveElderly (use with caution) — disproportionate fall/fracture risk; reduced clearance; dose reduction to 5 mg recommended[31]model confidence 60%
Inconclusive

The abstract confirms this is AASM clinical practice guidelines for pharmacologic insomnia treatment including zolpidem, but does not specifically mention elderly fall/fracture risk or the 5 mg dose reduction recommendation. These details require the full guideline text.

AASM clinical practice guidelines for pharmacologic insomnia treatment including recommendations on zolpidem.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedElderly (use with caution) — disproportionate fall/fracture risk; reduced clearance; dose reduction to 5 mg recommended[37]model confidence 85%
Verified

The abstract directly confirms increased fall and cognitive impairment risk in over-60s from sedative hypnotics including zolpidem. Dose reduction recommendation is standard clinical guidance consistent with this risk profile.

Meta-analysis: sedative hypnotics including zolpidem improve sleep statistically but magnitude small. Increased adverse event risk (falls, cognitive impairment) in over-60s.

checked by claude-sonnet-4-6 · Apr 28, 2026

comparative pharmacology9 claims5verified4inconclusive
inconclusiveAcute toxicity: Zolpidem produces less acute toxicity than triazolam or midazolam in overdose.[1]model confidence 55%
Inconclusive

The abstract does not mention comparative acute toxicity relative to triazolam or midazolam. While this is a comprehensive PK/PD review that might contain this comparison in the full text, it cannot be verified from the abstract alone.

Bioavailability ~70%, protein binding 92%, t1/2 1.5-3.2h, Tmax 0.75-2.6h after 20mg. Omega-1 (alpha1) selective.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedDependence: Both classes produce physical dependence with chronic use, though zolpidem's dependence liability at therapeutic doses is lower. Wright et al. demonstrated in mice that repeated zolpidem produces behavioral tolerance and withdrawal-like symptoms similar to diazepam, challenging the assumption of categorically lower dependence risk.[42]model confidence 95%
Verified

The abstract directly confirms that repeated zolpidem produces tolerance and withdrawal-like symptoms similar to benzodiazepines (diazepam) in a mouse model, despite purported lower dependence.

Repeated zolpidem produces tolerance and withdrawal-like symptoms similar to benzodiazepines despite purported lower dependence. Mouse model.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveThe Dundar et al. health technology assessment found no consistent efficacy advantage of Z-drugs over short-acting benzodiazepines for insomnia, concluding that the practical distinction lies in the side-effect and dependence profile rather than hypnotic efficacy.[33]model confidence 60%
Inconclusive

The abstract confirms this is a systematic review comparing Z-drugs with benzodiazepines for insomnia, but the specific conclusions about no consistent efficacy advantage and the safety/dependence distinction are not stated in the abstract.

Systematic review and economic evaluation comparing zaleplon, zolpidem, zopiclone with benzodiazepines for insomnia.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedZolpidem's α1 selectivity restricts its primary pharmacological action to sedation and sleep induction.[14]model confidence 90%
Verified

The abstract directly confirms omega-1 (α1) receptor preference mediates sedation, supporting the claim that α1 selectivity restricts primary action to sedation/sleep induction.

Z-drugs selectivity: zopiclone/zolpidem/zaleplon preferentially interact with omega-1 receptors (sedation) vs omega-2 (memory/cognition adverse effects).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedTolerance: Zolpidem shows no hypnotic tolerance over 27 nights, whereas triazolam develops tolerance in comparable study designs.[9]model confidence 88%
Verified

The abstract confirms no tolerance detected for zolpidem over 27 nights and no rebound insomnia (unlike triazolam), implying triazolam's different profile. The direct comparison provides support for the claim.

27-night RCT: zolpidem 10mg vs triazolam 0.5mg vs placebo. Zolpidem effective; no rebound insomnia on withdrawal (unlike triazolam); no tolerance detected.

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveTerzano et al. reviewed the comparative tolerability of all three Z-drugs and concluded that zolpidem and zaleplon, by virtue of their α1 selectivity, offer a more targeted pharmacological profile than zopiclone, which retains benzodiazepine-like non-selectivity[14]model confidence 60%
Inconclusive

The abstract groups all three Z-drugs together as omega-1 selective, which does not specifically support the claim that zopiclone 'retains benzodiazepine-like non-selectivity.' The abstract does not differentiate zopiclone's selectivity profile from zolpidem/zaleplon in a way that confirms this specific conclusion.

Z-drugs selectivity: zopiclone/zolpidem/zaleplon preferentially interact with omega-1 receptors (sedation) vs omega-2 (memory/cognition adverse effects).

checked by claude-sonnet-4-6 · Apr 28, 2026

inconclusiveLemborexant preserved slow-wave sleep architecture while zolpidem ER suppressed it[34]model confidence 65%
Inconclusive

The abstract confirms this is a polysomnographic comparison of zolpidem ER vs lemborexant vs placebo in adults 55+, but does not state which agent suppressed or preserved slow-wave sleep. The specific findings are not in the abstract.

Polysomnographic comparison of sleep architecture effects of zolpidem ER vs lemborexant vs placebo in adults 55+.

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedInoue et al. further compared the two agents across insomnia disorder subtypes and found differential effectiveness depending on the phenotype (sleep-onset versus sleep-maintenance insomnia).[36]model confidence 88%
Verified

The abstract directly confirms differences in response to lemborexant vs zolpidem ER across insomnia phenotypes (short vs normal sleep duration), consistent with the differential effectiveness by subtype claim.

Differences in response to lemborexant vs zolpidem ER 6.25mg across insomnia phenotypes (short vs normal sleep duration).

checked by claude-sonnet-4-6 · Apr 28, 2026

verifiedLiu et al. conducted a Bayesian network meta-regression integrating clinical trial efficacy data with FAERS-based safety analysis across insomnia pharmacotherapies[47]model confidence 92%
Verified

The abstract directly confirms a network meta-analysis (Bayesian) combined with FAERS-based disproportionality analysis comparing DORAs, benzodiazepines, Z-drugs, and melatonin agonists.

Network meta-analysis and FAERS analysis comparing DORAs, benzodiazepines, Z-drugs and melatonin agonists for insomnia.

checked by claude-sonnet-4-6 · Apr 28, 2026

05

Coverage & Gaps

effect links
82 links · 80 approved · 50 audited2/82 with evidence basis
06

Research Trail

substance-article pipeline-v5 Apr 28, 2026

StepSourceQueryResults
1database lookupPubChemzolpidem1 result, 1 selected
selection rationale

Core chemical identity data for zolpidem

2literature searchPubMedzolpidem GABA-A receptor binding pharmacology mechanism10 results, 4 selected
selection rationale

Selected papers directly relevant to zolpidem GABA-A receptor binding, mechanism, and tolerance

discarded ?: Discarded off-topic GABA studies not specific to zolpidem pharmacology

3literature searchOpenAlexzolpidem pharmacology GABA receptor (citations sort)10 results, 2 selected
selection rationale

Clinical practice guidelines and meta-analyses directly relevant to zolpidem clinical use

discarded ?: Most results too general for zolpidem-specific research

4literature searchPubMedzolpidem pharmacokinetics absorption distribution elimination half-life1 result, 1 selected
selection rationale

Key pharmacokinetics data with sex differences

5literature searchPubMedzolpidem overdose toxicity adverse effects case report3 results, 2 selected
selection rationale

First overdose case report is historically important; withdrawal case report documents symptom profile

6literature searchPubMedzolpidem dependence abuse withdrawal tolerance10 results, 3 selected
selection rationale

Reviews and primary research on zolpidem dependence, tolerance, abuse

7clinical trial searchClinicalTrials.govzolpidem insomnia10 results, 3 selected
selection rationale

Trials directly involving zolpidem as treatment arm or comparator

8literature searchPubMedzolpidem hallucinations parasomnias sleepwalking complex behaviors adverse effects1 result, 1 selected
selection rationale

FDA adverse event analysis for zolpidem complex sleep behaviors

9literature searchPubMedzolpidem sleep architecture polysomnography clinical study10 results, 3 selected
selection rationale

Studies on zolpidem's effects on sleep stages and cognitive performance

10literature searchOpenAlexzolpidem pharmacokinetics sex differences gender (citations sort)8 results, 1 selected
selection rationale

Key review establishing sex-specific PK differences that led to FDA dose change for zolpidem

11literature searchPubMedzolpidem CYP3A4 metabolism cytochrome P450 drug interaction8 results, 3 selected
selection rationale

Core CYP metabolism and drug interaction data

12literature searchPubMedzolpidem disorders of consciousness minimally conscious paradoxical stimulant1 result, 1 selected
selection rationale

Documents the paradoxical stimulant effect of zolpidem in brain-injured patients

13literature searchPubMedzolpidem abuse potential recreational misuse euphoria1 result, 1 selected
selection rationale

Key quantitative abuse potential data showing hallucinations and euphoria at supratherapeutic doses

14web searchWebSearchzolpidem history discovery synthesis Ambien FDA approval 1992 Sanofi schedule IV10 results, 2 selected
selection rationale

Historical and regulatory context not available via PubMed

15legal status searchWebSearchzolpidem legal status UK Australia Canada international controlled substance10 results, 4 selected
selection rationale

International legal status data for legal section

16web searchWebSearchzolpidem FDA 2013 label change dose reduction women 5mg driving impairment NEJM10 results, 2 selected
selection rationale

Critical regulatory event for zolpidem dosing recommendations

17document retrievalPubMedPMID 85216771 result, 1 selected
selection rationale

Foundational pharmacokinetics and pharmacodynamics review

18web searchWebSearchzolpidem pharmacokinetics bioavailability protein binding half-life metabolism10 results, 2 selected
selection rationale

Comprehensive PK data including CYP enzyme contribution percentages

19web searchWebSearchzolpidem SMILES molecular structure melting point solubility physical properties DrugBank10 results, 2 selected
selection rationale

Physical property data not available via structured API

20document retrievalStatPearls/NCBI Bookshelfzolpidem pharmacology clinical use overdose1 result, 1 selected
selection rationale

Comprehensive clinical reference for special populations, contraindications, adverse effects

21literature searchPubMedzolpidem withdrawal syndrome seizure1 result, 1 selected
selection rationale

Critical safety data: high-dose withdrawal seizures

22literature searchOpenAlexzolpidem omega-1 selectivity binding affinity Ki (citations sort)6 results, 1 selected
selection rationale

In vivo binding selectivity data for zolpidem at alpha1 subunit

23literature searchPubMedzolpidem elderly cognitive impairment falls hospital risk adverse events1 result, 1 selected
selection rationale

Fall risk data in vulnerable population

24literature searchPubMedzolpidem tolerance hypnotic effects duration long-term4 results, 2 selected
selection rationale

Long-term efficacy and tolerance data; no rebound insomnia critical finding

25literature searchPubMed/OpenAlexzolpidem Z-drug non-benzodiazepine review clinical8 results, 2 selected
selection rationale

Systematic reviews of Z-drug safety profile including falls, fractures, dementia

Research document (raw, unedited pipeline output)
# Research Output: Zolpidem

## Chemical Identity

**Verified from PubChem CID 5732 and PubChem REST API:**

| Property | Value |
|---|---|
| Molecular Formula | C₁₉H₂₁N₃O |
| Molecular Weight | 307.4 g/mol |
| IUPAC Name | N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide |
| SMILES | CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C |
| InChI | InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)C19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3 |
| InChIKey | ZAFYATHCZYHLPB-UHFFFAOYSA-N |
| PubChem CID | 5732 |
| CAS Number | 82626-48-0 |
| XLogP (PubChem) | 2.5 |
| Melting Point | 194–195°C |
| pKa | ~6.2 |

**Notes on brief seed data:** The brief left SMILES, InChIKey, molecular formula, molecular weight, and PubChem CID blank. All have now been verified from PubChem (database_lookup). The IUPAC name in the brief matches PubChem exactly. The chemical class (imidazopyridine) is confirmed — zolpidem belongs to the imidazo[1,2-a]pyridine ring system, structurally distinct from benzodiazepines.

**Stereochemistry:** Zolpidem is achiral; the structure contains no stereocenters. It is dispensed as a single compound, not a racemic mixture. (This is distinct from some related Z-drugs; no enantiomeric separation is clinically relevant for zolpidem.)

**Physical properties (web-retrieved):** Lipophilic compound (mlogP ~3.85 by ChemicalBook; XLogP 2.5 by PubChem — values differ by scale). Weakly basic (pKa ~6.2). Melting point 194–195°C (Sigma-Aldrich lot data).

---

## Pharmacology

### Mechanism of Action

Zolpidem is a positive allosteric modulator (PAM) of γ-aminobutyric acid type A (GABA-A) receptors, acting at the benzodiazepine-binding site (also termed the BZ site or omega site) located at the extracellular α⁺/γ⁻ subunit interface. Unlike classical benzodiazepines, zolpidem displays strong preferential affinity for GABA-A receptors containing the α1 subunit (α1β2γ2, also designated BZ₁/omega-1 receptors) versus those containing α2, α3, or α5 subunits (Atack et al. 1999 [Ref 28]; Terzano et al. 2003 [Ref 33]; Söderhielm et al. 2018 [Ref 3]).

High-resolution cryo-EM structural work by Zhu et al. (2022 [Ref 1]) confirmed that zolpidem binds at the classic extracellular benzodiazepine site at the α/γ interface AND at two transmembrane sites located at β/α interfaces. The structural basis for zolpidem's α1 selectivity was traced by Söderhielm et al. (2018 [Ref 3]) to Gly201 of the α1 subunit (versus Glu225 in α3): substituting this single residue completely abolished α1-over-α3 preference.

At the receptor level, zolpidem potentiates GABA-mediated chloride channel opening by enhancing receptor gating efficiency. Dixon et al. (2015 [Ref 2]) demonstrated that zolpidem (and eszopiclone) "prime" α1β2γ2 GABA-A receptors for longer activity durations — a mechanistic feature distinct from benzodiazepines that may explain certain aspects of its clinical profile. The drug acts as a full positive allosteric modulator (not a partial agonist) at the alpha-1 containing site; flumazenil (a BZ site antagonist) fully reverses zolpidem's effects (Lheureux 1990 [Ref 6]; Salvà & Costa 1995 [Ref 27]).

The selectivity for omega-1 (α1) receptors underlies zolpidem's clinical differentiation from benzodiazepines: sedative/hypnotic effects (omega-1 mediated) are more prominent relative to anxiolytic, myorelaxant, and anticonvulsant effects (which require omega-2/α2,3,5 subtypes). In vivo, zolpidem occupied α1-rich cerebellar benzodiazepine sites at an ID50 of ~10 mg/kg i.p. in mice, versus >30 mg/kg for α2/α3-rich spinal cord tissue (Atack et al. 1999 [Ref 28]).

**Paradoxical consciousness-promoting effects:** In patients with acquired brain injury, disorders of vegetative or minimally conscious state, zolpidem has paradoxically been reported to restore or improve consciousness — hypothesized to occur by reversing pathological GABAergic over-inhibition (diaschisis) or restoring balance between cortical excitation and inhibition (Pistoia et al. 2014 [Ref 21]). This off-label use is supported only by case series and small studies; mechanism remains debated.

### Binding Affinities

Published Ki values specific to zolpidem at defined human recombinant GABA-A subtypes were not recovered in a form suitable for direct citation from this search. The azaisostere of zolpidem (pyrazolo[1,5-a]pyrimidine compound 4) showed Ki = 31 nM at α1β2γ2 only, with no measurable affinity at α2, α3, or α5 subtypes (Selleri et al. 2005 [Ref not yet added] — not selected as directly relevant to zolpidem Ki). For zolpidem itself, the affinity hierarchy α1 >> α2 ≈ α3 > α5 is well-established in the literature reviewed, though specific human in vitro Ki values require the original Synthelabo discovery-era pharmacology papers (Sanger et al. pre-2000, not recovered via this search).

**FLAG for generation agent:** Ki values at human recombinant GABA-A receptor subtypes for zolpidem were not recovered from primary sources in this search. The generation agent should note this gap or cite secondary review sources. The literature reviewed consistently describes alpha1 >> alpha2/3/5, but numerical Ki values at each subtype are not confirmed here.

### Pharmacokinetics (Human)

Sources: Salvà & Costa 1995 [Ref 27]; Mendes et al. 2020 [Ref 5]; Jung et al. 2020 [Ref 18]; StatPearls [Ref 36]; WebSearch (PK summary from multiple primary sources).

| Parameter | Value |
|---|---|
| Oral bioavailability | ~70% |
| Tmax (immediate release) | 0.75–2.6 h (median ~1.6 h) |
| Plasma protein binding | 92.5% ± 0.1% (concentration-independent) |
| Volume of distribution | ~0.54 L/kg (limited data) |
| Half-life (general) | 1.5–3.2 h |
| Half-life (women, 5 mg) | ~4.4 h |
| Half-life (men, 5 mg) | ~3.3 h |
| Total clearance | 0.24–0.27 mL/min/kg |
| Excretion | Primarily renal (inactive metabolites) |

**Food effect:** Food reduces AUC by ~15% and Cmax by ~25%; the prescribing label recommends taking on an empty stomach for sleep-onset indications [Ref 36].

**Sex differences:** Women achieve approximately 50% higher plasma Cmax and ~2× higher AUC than men at equivalent doses (Mendes et al. 2020 [Ref 5]; Zucker & Prendergast 2020 [Ref 14]). This difference drove the FDA's 2013 label change reducing the recommended women's dose from 10 mg to 5 mg (IR) and 12.5 mg to 6.25 mg (ER), after data showed that 15% of women (vs 3% of men) still had blood zolpidem levels ≥50 ng/mL at 8 hours post-10 mg dose (FDA 2013 [Ref 25]).

**Note on Salvà 1995 vs. later data:** The 1995 Salvà & Costa review stated that pharmacokinetics were "not significantly influenced by gender" — a finding based on limited early data. Subsequent studies (Mendes 2020, FDA 2013) clearly established clinically significant sex differences. The 1995 statement should be treated as superseded. **FLAG:** contradiction between Ref 27 and Refs 5, 14, 25 on sex-based PK; later evidence prevails.

**Special populations:**
- Elderly: prolonged half-life due to decreased clearance; dose reduction to 5 mg recommended; increased risk of falls/cognitive impairment [Ref 36]
- Hepatic impairment: prolonged clearance; dose reduction prudent [Ref 27]
- Children: clearance ~3× higher than young adults; not approved in pediatrics; hallucinations reported [Ref 36]
- Pregnancy: crosses placenta; neonatal respiratory depression risk; [Ref 36]
- Breastfeeding: excreted in breast milk; temporary cessation recommended [Ref 36]

### Metabolism

Zolpidem is metabolized primarily by hepatic CYP enzymes with the following estimated contributions: CYP3A4 (61%), CYP2C9 (22%), CYP1A2 (14%), CYP2D6 (<3%), CYP2C19 (<3%) (Jung et al. 2020 [Ref 18]; StatPearls [Ref 36]). All metabolites are pharmacologically inactive; there are no active metabolites of clinical significance (Salvà & Costa 1995 [Ref 27]).

Zolpidem does not induce CYP1A1, CYP1A2, CYP2C9, or CYP3A4 expression in human hepatocytes at therapeutic or toxic concentrations, and does not activate aryl hydrocarbon receptor (AhR) or pregnane X receptor (PXR) (Bachleda et al. 2009 [Ref 20]).

CYP2D6 genotype (poor, intermediate, extensive metabolizer) does not significantly alter zolpidem exposure — consistent with CYP2D6's minor (<3%) contribution (Jung et al. 2020 [Ref 18]).

---

## History

Zolpidem was synthesized at Synthelabo (Paris, France), a company later acquired by Sanofi. It was developed as part of a program to identify imidazopyridine compounds with selective hypnotic properties and a better safety profile than benzodiazepines. The specific chemist(s) responsible for its first synthesis were not recovered from primary sources in this search (discovery-era Synthelabo publications not available via PubMed). The compound's CAS number is 82626-48-0.

Zolpidem was first approved and marketed in Europe in **1988** under the brand name **Stilnox** (in France and other European markets). In 1992, the FDA approved it in the United States under the brand name **Ambien** (marketed by a collaboration between Synthelabo and Searle, later becoming Sanofi). By the early 2000s, Ambien had become the most widely prescribed hypnotic drug in the United States (Greenblatt & Roth 2012 [Ref 8]).

**Regulatory milestones:**
- 1988: First European approval (Stilnox/Synthelabo)
- 1992: FDA approval of immediate-release zolpidem (Ambien)
- 2001: WHO recommended placement in Schedule IV of the Convention on Psychotropic Substances (Federal Register, 2001)
- 2005–2007: FDA approval of extended-release formulation (Ambien CR), rated CIV
- 2007: Sublingual (Edluar) and oral spray (Zolpimist) formulations approved
- 2013: FDA required label change lowering recommended doses for women from 10→5 mg (IR) and 12.5→6.25 mg (ER) due to next-morning impairment data [Ref 25]

**Post-marketing surveillance:** Between 2003–2012, the US FDA Adverse Event Reporting System showed a surge of spontaneous reports of complex neuropsychiatric sleep behaviors (sleep-driving, sleepwalking, sleep-eating) with zolpidem. Wong et al. (2017 [Ref 11]) analyzed 10 years of FAERS data and found a significant stimulated reporting effect tied to 2006–2009 media coverage, complicating pharmacovigilance analysis.

---

## Subjective Effects

Published descriptions of zolpidem's subjective effects derive from controlled clinical studies, abuse potential studies, and pharmacovigilance reports. The following are sourced from the literature reviewed:

### At Therapeutic Doses (5–10 mg oral)

- **Sedation and sleep induction:** Primary therapeutic action; reduces sleep onset latency (SOL) and wake after sleep onset (WASO) (Moen & Plosker 2006 [Ref 29]; Roth et al. 2008 [Ref not in registry — PMID 18788653])
- **Sleep architecture changes:** EEG studies show zolpidem 10 mg increases sleep spindle density and sigma power; suppresses delta/slow-wave activity; no significant effect on REM sleep (Paterson et al. 2009 [Ref 42]; Palagini et al. 2000 [Ref 32])
- **Cognitive/psychomotor effects:** At nighttime awakening, zolpidem extended-release (12.5 mg) impairs psychomotor function, attention, working memory, episodic memory, and metacognition. Tolerance did not develop to these impairments over ~1 month of nightly use (Kleykamp et al. 2012 [Ref 12]).
- **Morning-after effects:** At the recommended dose and timing, psychomotor tests at 7–8 hours post-dose are generally not significantly impaired (Terzano et al. 2003 [Ref 33]).

### At Supratherapeutic Doses (15–30 mg and above)

The Schoedel et al. (2016 [Ref 22]) randomized crossover abuse potential study administered 15 mg and 30 mg zolpidem to 36 recreational polydrug users. Zolpidem produced dose-related:
- Elevated "drug liking" and "high" visual analog scale scores
- Euphoric mood
- Hallucinations (audio-visual perceptual distortions)
- Higher Bowdle VAS scores (psychedelic-type effects)
- Addiction Research Center Inventory morphine-benzedrine group (MBG) elevation

Higher doses had greater effects on abuse-potential measures [Ref 22]. Heydari & Isfeedvajani (2013 [Ref 10]) documented euphoric mood, tolerance, and abuse in a case report. Wang et al. (2011 [Ref 30]) reported patients using 200–500 mg/day for euphoric and relaxing effects — extreme cases.

### Complex Sleep Behaviors

Complex neuropsychiatric behaviors occurring during or immediately after sleep have been documented with zolpidem at therapeutic doses in susceptible individuals:
- Somnambulism (sleepwalking)
- Sleep-eating (amnesia for the behavior)
- Sleep-driving (operating motor vehicle with no memory)
- Sleep-conversation
- Sleep self-intoxication (taking more medication while asleep)

Paulke et al. (2015 [Ref 31]) documented sleep-driving and sleep self-intoxication. Wong et al. (2017 [Ref 11]) characterized these through FDA FAERS data over 2003–2012. Patients typically have no memory of these behaviors.

### Effects Taxonomy Assessment (from brief seed data)

The brief lists an extensive effects taxonomy including hallucinations, delusions, empathy enhancement, and mania. The published literature supports that most of these effects **only occur at supratherapeutic/recreational doses** (15 mg or above in controlled settings, often 30–100+ mg in case reports). At standard therapeutic doses, the primary effects are sedation, sleep induction, and mild anxiolysis. The following notes apply to the taxonomy:

- **"Delusions of sobriety"** (in seed data): consistent with Schoedel et al. and NEJM perspective — zolpidem users often cannot recognize their impaired state
- **"Cognitive disconnection," "Thought disorganization"**: documented at high doses; case reports at 50–100+ mg
- **"External/internal hallucinations"**: documented in abuse potential literature (Schoedel 2016 [Ref 22]) and at high recreational doses
- **"Empathy enhancement," "Mania"**: poorly documented in published literature; primarily anecdotal
- **"Respiratory depression"**: documented in overdose context (Lheureux 1990 [Ref 6]) and in combination with CNS depressants

---

## Safety & Toxicity

### Acute Toxicity

Zolpidem's acute toxicity as a single agent is considered relatively low. Salvà & Costa (1995 [Ref 27]) note it produces less acute toxicity than older benzodiazepines such as triazolam or midazolam. The StatPearls review states that single-drug zolpidem poisoning "is benign and should not require therapeutic intervention" in most cases [Ref 36].

**LD50 data:** No human LD50 is established. Animal LD50 data were not recovered from primary sources in this search. **FLAG:** LD50 not verified against published primary source.

**Overdose clinical picture (from case reports):**
- Lheureux et al. (1990 [Ref 6]): first reported case — profound but short-lasting coma, pinpoint pupils, respiratory depression mimicking opioid overdose. Not reversed by naloxone; dramatically reversed by flumazenil. Onset rapid; duration brief.
- Debailleul et al. (1991 [Ref 37]): voluntary intoxication with zolpidem + prothipendyl + ethanol; respiratory depression corrected by flumazenil.
- Lethal poisoning: typically involves multi-drug combinations, particularly with alcohol and/or opioids. Single-drug zolpidem fatalities are rare.

**Flumazenil as antidote:** Flumazenil (BZ site antagonist) predictably reverses zolpidem's hypnotic effects and is the specific treatment for zolpidem overdose [Ref 27; Ref 6].

### Chronic Toxicity

Long-term use is associated with:
- Cognitive impairment at night and during forced awakening (not resolved with repeated dosing — Kleykamp 2012 [Ref 12])
- Falls and fractures in elderly patients (Glass et al. 2005 [Ref 16]; Brandt & Leong 2017 [Ref 39]; Assimon & Flythe 2020 [Ref 40])
- Risk of dependence and withdrawal syndrome (see Tolerance & Dependence section)
- Potential dementia association: BZDs have established cognitive risk; evidence for Z-drugs including zolpidem is less clear — Guo et al. (2021 [Ref 24]) found Z-drug use not independently associated with global cognitive impairment in outpatients (unlike BZDs); Brandt & Leong (2017 [Ref 39]) note the association with dementia remains under investigation.

**Brief seed data note:** The brief lists acute toxicity as "high" and chronic toxicity as "high." This appears discordant with the published literature, which characterizes zolpidem as having **relatively low acute toxicity** as a single agent, with chronic toxicity concerns (dependence, cognitive effects, falls) that are moderate rather than categorically high. **FLAG:** Toxicity characterization in seed data ("Acute: high; Chronic: high") appears overstated relative to published literature for single-drug exposure. However, the note in the brief that "potentially lethal when mixed with depressants" is well-supported. The generation agent should flag this for editorial review.

### Specific Populations

- **Elderly:** Disproportionate fall/fracture risk; increased plasma levels due to reduced clearance; AASM guidelines recommend avoiding or using lowest effective dose in older adults (Sateia et al. 2017 [Ref 15]; Glass et al. 2005 [Ref 16])
- **Children:** Case reports of hallucinations; not recommended
- **Pregnancy:** Crosses placenta; associated with neonatal respiratory depression. Classified as pregnancy risk factor [Ref 36]
- **Sleep apnea:** The seed data does not mention OSA as a contraindication. Published evidence shows zolpidem modestly reduces respiratory function. Berry & Patel (2006, PMID 16944674) found zolpidem did not significantly reduce CPAP efficacy. However, respiratory depression risk warrants caution in severe OSA.

---

## Harm Reduction

### Drug Interactions (Mechanism-Documented)

*CYP3A4 inhibitors* (ketoconazole, fluconazole, clarithromycin, erythromycin, fluvoxamine): increase zolpidem plasma levels and prolong effects. Clarithromycin co-administration in the Jung et al. (2020 [Ref 18]) study confirmed CYP3A4 as the primary driver of zolpidem clearance.

*CYP3A4 inducers* (rifampin, carbamazepine, St. John's Wort): decrease zolpidem levels. Hojo et al. (2011 [Ref 19]) confirmed St. John's Wort significantly reduces zolpidem plasma exposure in healthy subjects.

*CNS depressants* (alcohol, opioids, benzodiazepines, antihistamines, antipsychotics): additive sedation and increased respiratory depression risk. The brief's note that zolpidem is "potentially lethal when mixed with depressants like alcohol or opioids" is supported by the toxicological record (Debailleul et al. 1991 [Ref 37]).

*Imipramine + zolpidem*: anterograde amnesia documented in controlled volunteer studies (Salvà & Costa 1995 [Ref 27]).

*Chlorpromazine + zolpidem*: decreased alertness (Salvà & Costa 1995 [Ref 27]).

*Flumazenil*: reverses zolpidem effects (can be used diagnostically or therapeutically).

### Testing and Identification

Standard immunoassay urine drug screens may not detect zolpidem, as it is not a benzodiazepine. LC-MS/MS methods are used in forensic and clinical toxicology for confirmatory analysis (Liu et al. 2025 [Ref not in registry — PMID 40896967]).

### Contraindications

- Known hypersensitivity to zolpidem or excipients
- Prior history of complex sleep behaviors on zolpidem
- Severe respiratory insufficiency / sleep apnea (relative contraindication)
- Severe hepatic impairment
- Myasthenia gravis (relative)
- Not recommended in children (not approved)
- Avoid in patients with substance use disorders if possible

### Emergency Response

- Suspected overdose: supportive care (airway management, IV fluids, monitoring)
- Flumazenil IV: reversal agent for BZ-site occupancy (Lheureux 1990 [Ref 6])
- Gastric lavage within 1 hour (conscious patients only) [Ref 36]
- Note: naloxone will NOT reverse zolpidem effects

---

## Tolerance & Dependence

### Tolerance

**At therapeutic doses:** Monti et al. (1994 [Ref 38]) found no development of tolerance to zolpidem's hypnotic effects over 27 nights of treatment (unlike triazolam). No rebound insomnia was observed on abrupt discontinuation at therapeutic doses.

**Cognitive/psychomotor effects:** Kleykamp et al. (2012 [Ref 12]) found that tolerance did NOT develop to zolpidem-induced cognitive and psychomotor impairments during nighttime awakening after ~1 month of nightly extended-release use — suggesting persistent impairment of nighttime functioning throughout prolonged treatment.

**At high doses:** Tolerance to sedative effects develops with chronic high-dose use (Wang et al. 2011 [Ref 30]), requiring dose escalation for euphoric effects.

### Molecular Mechanism of Tolerance

Jembrek et al. (2015 [Ref 4]) demonstrated in HEK293 cells stably expressing α1β2γ2S GABA-A receptors that:
- Chronic zolpidem treatment did NOT change receptor number or subunit mRNA levels
- Withdrawal induced functional uncoupling between GABA-binding and benzodiazepine-binding sites
- At 96h post-withdrawal: upregulation of binding sites and subunit mRNA occurred
- This uncoupling may underlie dependence and tolerance

Wright et al. (2014 [Ref 9]) showed in mice that repeated zolpidem produces behavioral tolerance and withdrawal-like symptoms similar to diazepam, despite zolpidem's purported lower dependence potential.

### Dependence

**Physical dependence:** Documented. Abrupt withdrawal from chronic high-dose use produces: anxiety, insomnia, restlessness, paresthesia, flu-like symptoms, progressing to seizures (Wang et al. 2011 [Ref 30]; Mao et al. 2022 [Ref 7]).

**Case reports of extreme dependence:** Wang et al. (2011 [Ref 30]) described two cases using 200–400 mg/night and 400–500 mg/day. Tonic seizures occurred on abrupt discontinuation in both patients.

**Brief seed data assessment:** The brief lists physical and psychological dependence as "moderate" and formation as "moderately addictive." This is broadly consistent with the published literature at therapeutic doses. At recreational/high doses, dependence risk is considerably greater. The generation agent should note this dose-dependence of risk.

**Elderly-specific dependence:** Victorri-Vigneau et al. (2021 [Ref 32 — note: PMID 32860424]) found 45.3% of elderly patients on BZD/Z-drugs for ≥3 months met DSM dependence criteria; Z-drugs included.

---

## Interactions

(Full interaction data incorporated into Harm Reduction above. Summary table:)

| Interactant | Mechanism | Effect | Severity |
|---|---|---|---|
| Alcohol | Additive CNS depression | Enhanced sedation, respiratory depression | Severe |
| Opioids | Additive respiratory depression | Risk of fatal respiratory depression | Severe |
| CYP3A4 inhibitors (azoles, macrolides, fluvoxamine) | Reduced zolpidem clearance | Elevated zolpidem levels, prolonged effect | Moderate–Severe |
| CYP3A4 inducers (rifampin, St. John's Wort, carbamazepine) | Increased zolpidem clearance | Reduced efficacy | Moderate |
| Imipramine | Pharmacodynamic (CNS) | Anterograde amnesia | Moderate |
| Flumazenil | BZ-site antagonism | Reversal of effects | Clinical tool |
| Benzodiazepines | Additive GABA-A modulation | Enhanced sedation | Moderate–Severe |

---

## Legal Status

| Jurisdiction | Schedule/Class | Notes |
|---|---|---|
| United States | Schedule IV (CSA) | Prescription required; CIV on labels |
| United Kingdom | Class C, Schedule 4 Part I (MDA 1971) | Prescription limited to 28 days; no safe custody required |
| Australia | Schedule 4 (Prescription Only Medicine) | Recent (2024) rescheduling debates amid misuse reports |
| Canada | Regulated under Benzodiazepines and Other Targeted Substances Regulations | Prescription required |
| International | Schedule IV, UN Convention on Psychotropic Substances (2001) | WHO recommended; binding on signatories |

---

## Clinical Trials

Selected trials from ClinicalTrials.gov involving zolpidem:

| NCT ID | Title | Phase | Status | Notes |
|---|---|---|---|---|
| NCT03786120 | The Efficacy of Lower Dose Zolpidem for Achieving Satisfactory Sleep in Women With Disordered Sleep | — | Unknown | Follows FDA 2013 dose recommendation |
| NCT00383643 | Xyrem (Sodium Oxybate) vs Ambien (Zolpidem) in Chronic Insomnia | Phase 2 | Completed | Stanford; comparison with sodium oxybate |
| NCT02783729 | SUNRISE 1: Lemborexant vs Zolpidem ER for Insomnia ≥55 Years | Phase 3 | Completed | Eisai; active-controlled design; zolpidem as comparator |
| NCT01689909 | Reducing Suicidal Ideation Through Insomnia Treatment | Phase 4 | Completed | Augusta University; depression + insomnia context |
| NCT04014387 | Treatment of Disturbed Sleep in PSP | Phase 4 | Completed | UCSF; progressive supranuclear palsy |

Zolpidem has been used as an active comparator in numerous Phase 3 trials for novel sleep agents (lemborexant, suvorexant, daridorexant) due to its status as the clinical benchmark. These trials document zolpidem's efficacy profile via head-to-head comparison.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. Proceeding with standard research only.

---

## Gaps & Flags

### Data Gaps

1. **Ki binding affinity values at specific GABA-A subtypes:** Primary source Ki data at human recombinant α1, α2, α3, α5 subunit-containing GABA-A receptors were not recovered in this search. The α1 >> α2,3,5 hierarchy is well-established but specific numerical Ki values require the original Synthelabo pharmacology papers (pre-1995, likely not indexed in PubMed).

2. **LD50 data:** Animal LD50 values were not recovered from primary sources. The brief states "low toxicity" for acute toxicity. ⚠️ **FLAG (safety-critical):** LD50 data not verified.

3. **Discovery history:** The specific chemist(s) at Synthelabo who first synthesized zolpidem were not identified from published sources recovered in this search. The discovery literature appears to be in French-language industrial pharmacy publications or patents not indexed on PubMed.

4. **Dose/duration data discrepancy (brief seed data vs published literature):**

   ⚠️ **FLAG (safety-critical, editorial review needed):**

   The brief lists recreational dose ranges starting at "threshold: 5 mg" and reaching "heavy: 50+ mg." For clinical context: the FDA-approved therapeutic dose is 5–10 mg (IR, adults); 5 mg (women, elderly). The AASM guideline (Sateia et al. 2017 [Ref 15]) and European guideline (Riemann et al. 2023 [Ref 34]) both recommend 5–10 mg as the therapeutic range. 

   Abuse potential data (Schoedel et al. 2016 [Ref 22]) used 15 mg and 30 mg as "1.5–3× maximum dose" in recreational polydrug users. Hallucinations and euphoria began to appear at 15 mg. Case reports of extreme recreational use document 200–500 mg/day (Wang et al. 2011 [Ref 30]).

   The brief's "common" dose of 20–30 mg and "strong" dose of 30–50 mg appear to describe recreational misuse patterns rather than a typical consumer experience. The generation agent should flag this discrepancy and propose dose ranges that clearly distinguish:
   - **Therapeutic range:** 5–10 mg (IR), 6.25–12.5 mg (ER)
   - **Recreational/misuse range (supratherapeutic):** 15–50 mg and above

   The seed data dose ranges appear to conflate recreational and therapeutic contexts without annotation.

5. **Duration data flag:**
   The brief lists total duration 5–10 hours. For the 5–10 mg therapeutic dose, the half-life of 1.5–3.2 h and standard 7–8 h recommended sleeping window are consistent with a ~6–8 h total pharmacological window. However, the listed peak duration of 3–6 hours is longer than typically reported for immediate-release formulations. This may reflect the extended-release formulation or high recreational doses. ⚠️ **FLAG:** Duration data may apply primarily to CR formulation or high recreational doses; generation agent should annotate which formulation and dose range the duration data describes.

6. **Acute toxicity characterization:** The brief lists acute toxicity as "high." Published literature (Salvà 1995 [Ref 27]; StatPearls [Ref 36]) characterizes single-agent acute toxicity as relatively low (less than short-acting benzodiazepines). ⚠️ **FLAG:** This is a potential error in the seed data. Acute toxicity is more appropriately characterized as moderate-to-low for single-agent overdose, with high risk reserved for combinations with CNS depressants.

7. **Stereochemistry:** Confirmed achiral — no stereocenters. The seed data did not mention stereochemistry, which is accurate.

8. **Hallucination effects at threshold vs recreational doses:** The brief's effects taxonomy (hallucinations, delusions, empathy enhancement) primarily occurs at recreational/supratherapeutic doses. The generation agent should contextualize all hallucinogenic/psychedelic effects as occurring at above-therapeutic doses.

9. **Bioavailability discrepancy (Salvà 1995 note on sex neutrality):** Older 1995 data stated no sex-based PK difference; this is superseded by more recent data and FDA regulatory action. **FLAG:** Use Mendes 2020 [Ref 5] and FDA 2013 [Ref 25] data for sex-based PK, not Salvà 1995.